Neuronal death in Alzheimer's disease and therapeutic opportunities by Donev, Rossen Mintchev et al.
Neuronal death in Alzheimer’s disease 
and therapeutic opportunities
Rossen Donev a, Martin Kolev a, Bruno Millet b, Johannes Thome c, *
a Department of Medical Biochemistry and Immunology, School of Medicine, Cardiff University, Heath Park, Cardiff, UK
b Service Hospito-Universitaire de Psychiatrie Adulte, Centre Hospitalier Guillaume-Regnier, Université Rennes, Rennes, France
c Academic Unit of Psychiatry, Institute of Life Science, The School of Medicine, Swansea University, Swansea, UK
Received: May 20, 2009; Accepted: August 24, 2009
Abstract
Alzheimer’s disease (AD) is an age-related neurodegenerative disease that affects approximately 24 million people worldwide. A num-
ber of different risk factors have been implicated in AD; however, neuritic (amyloid) plaques are considered as one of the defining risk
factors and pathological hallmarks of the disease. In the past decade, enormous efforts have been devoted to understand the genetics
and molecular pathogenesis leading to neuronal death in AD, which has been transferred into extensive experimental approaches aimed
at reversing disease progression. Modern medicine is facing an increasing number of treatments available for vascular and neurodegen-
erative brain diseases, but no causal or neuroprotective treatment has yet been established. Almost all neurological conditions are char-
acterized by progressive neuronal dysfunction, which, regardless of the pathogenetic mechanism, finally leads to neuronal death. The
particular emphasis of this review is on risk factors and mechanisms resulting in neuronal loss in AD and current and prospective oppor-
tunities for therapeutic interventions. This review discusses these issues with a view to inspiring the development of new agents that
could be useful for the treatment of AD.
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Introduction
Alzheimer disease (AD) is a neurodegenerative disease that
causes changes in brain function. AD usually affects people
over the age of 65 years, with a plethora of devastating clinical
symptoms such as progressive decline in memory, thinking,
language and learning capacity. Age is the strongest predictor
for the development and progression of AD and with the rapidly
aging population, AD clearly poses a major health problem and
socio-economic burden. An estimated 5–10% of the population
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aged 65 years and over, and 40% of the population greater than
85 years of age are likely to be affected [1]. The genetic predis-
position accounts for only 5–10% and is associated with early
onset [2, 3].
Given the aging population in Western countries, the grave suf-
fering of the many individuals concerned and their families, and
the increasing economic cost of AD in terms of both healthcare
expenses and lost wages it makes it important to understand the
disease mechanisms and propose effective treatment strategies.
The clinical manifestation of AD is considered to be correlated with
the degree of neuronal loss in the brain and more specifically in
hippocampal and neocortical areas. While AD can be identified
based on clinical symptoms and by excluding other conditions
with similar phenomenology and psychopathology, a definite diag-
nosis is only possible post-mortem by histological analysis of the
patient’s brain. Extracellular senile (amyloid) plaques and intracel-
lular neurofibrillary tangles (NFTs) are considered to be hallmarks
of the disease [4]. Senile plaques contain extracellular deposits of
amyloid- protein (A), -synuclein, ubiquitin and apolipoprotein
E. NFTs are intracellular and extracellular aggregates of hyper-
phosphorylated  protein and apolipoprotein E [5]. Evidence that
A alone is not sufficient for initiating the pathophysiological cas-
cade of AD came from experiments with transgenic mice, which
suggested that sustained brain inflammation might be another
essential factor in AD pathogenesis. Different inflammatory mark-
ers such as activated microglia and astrocytes, elevated levels of
various cytokines and complement activation products are found
in AD brains [6]. Complement proteins are reported to be integral
components of amyloid plaques and cerebral vascular amyloid in
AD. They are found at the earliest stages of amyloid deposition
and their activation coincides with the progressive clinical mani-
festation of AD [7, 8].
Here we review the interrelationship between different risk 
factors for AD aetiology with particular emphasis on their role for
neuronal death as well as different strategies for neuroprotection
as a potentially promising therapeutic strategy.
Origin of the disease and mechanisms
for neuronal death in AD
The pathogenesis of AD is not yet fully understood. Various
hypotheses with respect to disease aetiology have been proposed
and those that are most widely accepted on grounds of a solid
experimental data base and clinical evidence are described below.
Inflammatory reaction
This hypothesis is based on observations that non-steroidal anti-
inflammatory drugs (NSAIDs) can reduce neurotoxins in patients
suffering from AD. In epidemiological and clinical studies, it was
initially noted that patients on high doses of anti-inflammatory
drugs exhibit a reduced incidence of AD and reduced the AD
symptoms [9–14]. However, this hypothesis became even more
attractive when it was demonstrated that the mediators and prod-
ucts of inflammatory reaction, such as cytokines [15, 16], comple-
ment proteins (reviewed in [17]), free radicals [18, 19], adhesion
molecules [20, 21] and prostaglandins (reviewed in [22]), were
neurotoxic in experiments with neural models. These products of
inflammatory reactions may represent extracellular signals which
initiate and promote neuronal degeneration in AD. For instance,
long-time administration of NSAIDs to arthritic patients can
reduce the risk of developing AD [7, 11]. Potent inflammatory
molecules, such as cytokines, chemokines and complement fac-
tors, are present in both cerebrospinal fluid (CSF) and plaques
from patients with AD [7]. Aggregated peptides, such as A are
shown to induce the production of pro-inflammatory cytokines
like interleukin (IL)-1, tumour necrosis factor (TNF)- and
chemokines (MIP-1, MIP-1, MCP-1) by microglial cells
[23–25]. These inflammatory molecules were found to be toxic in
neuronal models of AD and were implicated in extracellular sig-
nalling which initiated and promoted neuronal degeneration in AD.
Several intracellular signals are candidates for mediating actions
of inflammatory factors inside the cells such as A [26, 27], ubiq-
uitin [28, 29] and proteasome [30–32]. The observed protective
effect of NSAIDs could be due to a reduction of microglial activa-
tion and/or decreased generation of A [33, 34]. These observa-
tions are additionally confirmed by in vitro studies with human
neuronal cells which seem to be protected from the toxic effects
of A by NSAIDs [35].
While epidemiological and experimental studies lend strong
support for neuroinflammatory responses as drivers of AD patho-
genesis, recent in vivo studies also support a beneficial role for
such reactions (reviewed in [36]). A very strong support for the
beneficial impact of neuroinflammation on neuronal survival and
function came recently from a study with transgenic mice with
brain-directed overexpression of human soluble IL-1 receptor
antagonist [37]. Chronic blockade of IL-1 signalling in the brain of
these animals was found associated with an atrophic phenotype of
the brain and with modified levels of the amyloid precursor pro-
tein (APP) and presenilin 1 (PS1), a critical component of APP
processing machinery (discussed below). A number of reports
have provided evidence that activation of microglia and the subse-
quent degradation of amyloid plaques may underlie this phenom-
enon. These observations in animal models challenge earlier
assumptions that IL-1 elevation and resulting neuroinflammatory
processes play a purely detrimental role in AD, and prompt a need
for new characterizations of IL-1 function.
A-induced neurotoxicity
The extracellular A deposition has attracted major attention as a
cause of cytotoxicity in AD. The original ‘amyloid hypothesis’
argues that A deposition is the initiator for AD pathogenesis,
based on the following facts: A is a major component of the
amyloid plaques [38]; the deposition of A occurs prior to other
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pathological events such as NFT formation and neuronal loss [39];
synthetic A peptides, particularly A1–42/43, induce neuronal
death in vitro [40, 41]. A is proteolytically derived from the -
APP by the action of - and -secretases [42] (Fig. 1). These
enzymes cleave at the N-terminus of the A region of APP fol-
lowed by cleavage at the C terminus producing peptides of a
length of 39 to 43 amino acids. The two forms found predomi-
nantly in amyloid plaques and believed to be associated with the
disease, are 40 and 42 amino acids long. Alternatively, the -sec-
retase cleaves APP within the A domain yielding a non-toxic C
terminal fragment, followed by -secretase cleavage resulting in a
C terminal fragment- and a small peptide called P3 that is not
considered amyloidogenic. Presenilins (PS1 and PS2) regulate the
activity of -secretase and are involved in the processing of APP
and in the generation of A peptides [43] (Fig. 1). Presenilins were
first identified as enzymes acting as -secretase [44]. More
recently, it was discovered that presenilins are part of a tetrameric
complex comprised the proteins nicastrin, Aph1 (anterior phar-
ynx-defective phenotype) and Pen2 (presenilin enhancer) that
altogether regulate the production of A peptides [45, 46]. In AD
patients carrying missense mutations on either of the genes for
PS1 or PS2, it was reported that the overall levels of A peptides
were increased in the plasma, and that levels of the more amy-
loidogenic A42 were increased in cultured fibroblasts of patients
carrying inherited mutations on the genes for presenilins [47–49].
Experiments with animal models lacking expression of either PS1
or PS2 showed that between the two presenilins PS1 plays a
major role regulating the activity of -secretase and thus A forma-
tion [50, 51]. This new knowledge opens new hypotheses about the
mechanism that orchestrates the regulated intra-membrane prote-
olysis in -secretase substrates and in APP in particular.
Interestingly, presenilins have been implicated not only in reg-
ulation of activity of -secretase but also in control of apoptotic
machinery [52, 53]. AD associated presenilins showed to be
 substrates for proteolytic degradation. These investigations
strongly suggest that alternative presenilin fragments could regu-
late cell survival. Furthermore, mutations in presenilin genes,
which likely suppress proteolytic degradation of these proteins,
sensitize neurons to apoptosis by different mechanisms (e.g.
increased caspase-3 activation, production of oxyradicals, calcium
signalling dysregulation). These data demonstrate the complex
dual nature of regulation of neuronal death in AD by presenilins
and suggest that any treatment targeting these proteins might be
a double-edged sword and should be carefully considered.
Accumulated A induces multiple cytotoxic effects, including
oxidative stress, and alternation of ionic homeostasis in neurons
[54, 55]. A also alters the activities of various kinases, including
GSK3, cdk5, PKA and causes hyperphosphorylation of  protein,
leading to NFT formation [56–58]. These A-initiated toxicities
directly or indirectly induce neuronal cell death. Although this
classical A hypothesis does explain some of the mechanisms
underlying the pathogenesis and progression of AD, there is also
evidence against this hypothesis. For example, the quantity of A
deposits does not correlate with clinical features, as senile plaques
are also found in brains of elderly subjects without dementia [59].
Accumulation of senile plaques does not necessarily correlate
with the amount of synaptic loss [60, 61] and the severity of the
clinical manifestation [62]. In addition, several lines of transgenic
membrane fragment is then cleaved by -secretase, yielding a membrane-bound C-terminal fragment and a soluble N-terminal fragment (A). While
A is required for neuronal function, it can aggregate in the extracellular space of the brain to form amyloid plaques.
Fig. 1 Processing of APP. APP can be
processed by different sets of enzymes:
one pathway leads to amyloid plaque for-
mation (amyloidogenic), while the other
does not (non-amyloidogenic). In the non-
amyloidogenic pathway, APP is cleaved
first by -secretase to yield a soluble 
N-terminal fragment and a C-terminal
fragment integrated within the cellular
membrane. The soluble protein may be
involved in the enhancement of synapto-
genesis, neurite outgrowth and neuronal
survival, and is considered to be neuro-
protective. The membrane fragment of the
cleaved APP is acted upon by -secretase,
a tetrameric complex comprised prese-
nilins, nicastrin, Aph1 and Pen2, to yield a
soluble N-terminal fragment (P3) and a
membrane-bound C-terminal fragment. In
the amyloidogenic pathway, APP is
cleaved first by -secretase, yielding a
soluble N-terminal fragment and a mem-
brane-bound C-terminal fragment. The
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mice with human familial AD mutant genes show considerable 
A deposits in brain without exhibiting other AD-specific patho-
logical features or behavioural abnormalities. Even though some
evidence suggest that the A deposition alone is not sufficient for
the development of AD, formation of the senile plaques seems to
be involved in triggering most of the subsequent pathogenetic
phenomena.
Although neurotoxicity of A has been initially attributed to its
fibrillar forms, more recent studies showed that neurotoxins also
comprise small diffusible A oligomers called A-derived dif-
fusible ligands (ADDLs), which were found to kill mature neurons
in organotypic central nervous system (CNS) cultures [63]. At cell
surfaces, ADDLs bound to trypsin-sensitive sites and surface-
derived tryptic peptides blocked binding and afforded neuropro-
tection. Remarkably, neurological dysfunction evoked by ADDLs
occurred well in advance of cellular degeneration. Recently it has
been demonstrated that non-fibrillar assemblies of A possess
electrophysiological activity, with the corollary that they may pro-
duce dementia by disrupting neuronal signalling prior to cell death
[64]. Recent experiments have detected the presence of ADDLs in
AD-afflicted brain tissue and in transgenic mice models of AD
[65–67]. The presence of high affinity ADDL binding proteins in
hippocampus and frontal cortex but not cerebellum parallels the
regional specificity of AD pathology and suggests involvement of
a toxin receptor-mediated mechanism. The properties of ADDLs
and their presence in AD-distressed brain are consistent with their
putative role even in the earliest stages of AD, including forms of
mild cognitive impairment. Considering the central role of A in
AD pathology, A peptides and mechanisms for their formation
have been the primary target in a number of contemporary
attempts to develop therapeutic agents against AD.
Complement-mediated neurodegeneration
Although viewed for years as a so-called immuno-privileged organ,
the CNS contains and synthesizes many components of the immune
system. Both glia and nerve cells in the brain can synthesize
immunoglobulins [68] and complement components [69, 70]. Brain
cells can express all of the complement components and should
thus be considered as an important source of complement [71].
The two major fibrillar amyloid forms A40 and A42 directly
activate the alternative and classical pathways of the complement
system by binding to C3 and the globular B head of C1q resulting
in the formation of pro-inflammatory molecules such as C3a, C5a
and membrane attack complex (MAC). MAC permeabilizes the cell
membrane, which can result in cell lysis (Fig. 2). Astrocytes and
microglia in the CNS produce both soluble complement regulatory
proteins (CReg) and membrane-bound CReg (CD59, CD55, CD46)
[72], which ensures a good level of protection against comple-
ment lysis by inhibiting MAC formation. However, the same can-
not be said for neurons. There is very little information regarding
the expression of CReg in neuronal cells. Studies to date suggest
that cultured primary neurons express only low levels of the mem-
brane CReg (mCReg), CD59 and CD55 [73, 74]. Furthermore, in
the frontal cortex and hippocampus of AD brains, a significant
decrease in the expression of CD59 at both protein and mRNA lev-
els was found when compared with brains of age-matched control
individuals without dementia [75]. An interesting hypothesis sug-
gests that at sublytic concentrations, MAC can alter the function of
neurons by triggering various cellular signalling pathways [8];
however, this needs to be further explored and corroborated in fur-
ther systematic investigations.
There is recent evidence that complement may also play a pro-
tective role in AD brain. The most convincing data for the protective
role of components of the complement cascade demonstrate that
production of C5a results in an activation of the neuroprotective
mitogen activated protein kinases [76] (Fig. 2). Furthermore,
animals genetically deficient in the complement component C5
were found to be more susceptible to hippocampal excitotoxic
lesions [77]. These findings suggest a novel non-inflammatory
role for C5a in modulating neuronal responses to excitotoxins.
More recently, the protective role of the early activation stages of
the complement cascade in AD was demonstrated in transgenic
mice with human APP, in which complement was blocked by
expression of soluble Crry (a rodent CReg with inhibitory activities
similar to human CD46 and CD55) [78]. Results showed that mice
expressing soluble Crry had a 2–3-fold increase in A accumula-
tion and neuronal degeneration compared to animals that did not
express the inhibitor. However, Crry inhibits C3 activation, and
thus prevents generation of C5a. It was suggested that the
observed effect might be due to decreased C5a formation. Another
recent study found that C1q protected cultured primary neurons
against A and SAP (serum amyloid P) induced neurotoxicity
[79]. The exact mechanism of this protection has not yet been elu-
cidated but the data suggest that C1q does not protect from A
induced apoptosis. However, considering the protective role of
C5a, the C1q-mediated defence against senile plaques might be at
least in part due to the generation of C5a. This speculation is sup-
ported by a recently published in vivo study on C3 deficient APP
transgenic mice that demonstrated accelerated plaque deposition
and neurodegeneration compared to C3 sufficient animals [80].
Although it is still disputable if complement system is a primary
cause of neuronal degeneration or a secondary event in AD [81], the
findings discussed above demonstrate that complement not only
lyses neurons, but also generates inflammation resulting in an
amplification of AD risk factors and neuronal death [17]. Thus, tar-
geting the complement cascade seems an attractive candidate strat-
egy for treating AD and other neurodegenerative diseases. However,
complement seems to possess a dual, ambiguous role in the patho-
genesis and progression of the AD which needs to be carefully con-
sidered when choosing targets for therapeutics to be developed.
Oxidative and nitrosylative damage
This hypothesis emphasizes the role of reactive oxygen and nitro-
gen species (ROS or RNS) in initiation and promotion of neurode-
generation in the brains of AD patients [18, 19]. Some of these
radicals originate from normal brain function processes: it is
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known that the brain utilizes about 25% of respired oxygen and
that about 2% of the oxygen consumed converts into ROS. Other
free radicals are released during inflammatory reactions and by
A. This hypothesis for the AD aetiology is supported by the
observation in some clinical trials that high doses of antioxidants
might be beneficial to AD patients [82, 83].
Increased oxidative stress may enhance intracellular accumu-
lation of A in neurons [84]. In addition, studies show that mem-
branes containing oxidatively damaged phospholipids accumu-
lated A faster than membranes containing only normal saturated
phospholipids [85]. Based on this finding, it was proposed that
one or some of the mechanisms of action in A neurotoxicity
might be free-radical mediated [86]. Further studies on protection
of cultured neuronal cells against A-induced toxicity by vitamin E
supported this hypothesis [87]. Additional evidence of increased
oxidative stress in AD include: AD patients have lower levels of
vitamins A, E and -carotene in their serum compared to control
patients [88]; increased consumption of oxygen is found in AD
patients [89]; activation of calcium-dependent neural proteinase
(calpain), triggering formation of free radicals, was found in AD
autopsy brain samples [90]; homogenates of frontal cortex from
such autopsy samples revealed a 22% higher production of free
radicals than those of age-matched controls [91]; increased neu-
ronal nitric oxide synthase (nNOS) expression in reactive astro-
cytes correlated with apoptosis in hippocampal neurons of post-
mortem brains from AD patients [92]; glutamine synthetase, a
highly sensitive enzyme to oxidative stress, showed decreased
activity in the AD autopsy brains [93]; increased levels of oxidized
proteins are found in the blood of AD patients when compared
with non-AD controls [93].
Proteasome inhibitor-induced neurotoxicity
Numerous studies now clearly demonstrate that inhibition of the
proteasome is sufficient to induce cell death in both neuronal and
© 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 2 Activation of complement system
by the amyloid plaques and its dual role in
neuronal death. C1q binds to the boxed
sequence in aggregated amyloid peptides
and activates classical pathway of comple-
ment system. This leads to cleavage of C3
to C3b which could bind to a different
sequence from the amyloid peptide
(boxed). C3b initiates generation of C5-
convertase cleaving C5 into C5a and C5b.
C5a interacts with the C5a receptor
(C5aR) on the surface of neurons and acti-
vates the neuroprotective mitogen acti-
vated protein kinases. On the other hand,
C5b initiates the terminal pathway of com-
plement cascade which forms MAC which
integrates into membrane of the weakly
protected neurons resulting in their death.
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glial cells. These studies have shown that proteasome inhibitors
can induce hallmarks of apoptosis, including caspase activation,
cytochrome C release, elevated p53 expression, chromatin frag-
mentation and DNA laddering [94–99]. The induction of such a
wide variety of cell death events by proteasome inhibitors sug-
gests a critical role for proteasome activity in neuronal homeosta-
sis. The proteasome is directly responsible for the degradation of
a number of cell death factors and its inhibition is sufficient to
increase their levels to a cytotoxic level. Furthermore, the protea-
some prevents accumulation of proteins not directly related to cell
death, but which can contribute to neuron death by conferring an
increased half-life of neurotoxic proteins. For example, protea-
some inhibition has been shown to increase the accumulation of
cytotoxic A [100, 101] and presenilin [102, 103]. It has been
shown that heat shock proteins (HSPs) can enhance proteasome-
mediated proteolysis [104, 105].
However, proteasome inhibition does not induce neuronal
death in all neuron populations or experimental setups [106, 107].
It seems that proteasome inhibitor-induced toxicity is cell-type
specific. It was demonstrated that proteasome inhibition could
have very different effects on cell death based on the differential
role of NF-B – a downstream proteasome target which can have
pro-apoptotic or anti-apoptotic effects depending on cell type
[108, 109]. In transferring the knowledge obtained from in vitro
studies to studies in the mature CNS, it is important to consider
the fact that the majority of in vitro studies are conducted in cul-
tures established from embryonic tissues or early postnatal brain.
One thus must take into account the possibility that embryonic tis-
sue may have a different dependence on proteasome activity than
established neurons within the developed and mature, or, as in the
case of AD patients, aged CNS.
Only recently, the importance of the proteasome in the phys-
iology and pathology of the CNS has begun to emerge. It is
likely that studies on this intriguing enzyme will yield further
important information on how oxidative stress occurs in the
CNS and how CNS protein turnover is regulated. Ultimately, this
may lead to the design of useful new therapeutic strategies
aimed at eliminating oxidative stress toxicity in the CNS,
thereby contributing to the prevention and/or amelioration of
clinical AD symptoms.
Cholesterol-induced neurotoxicity
All mammalian cells require cholesterol for the formation and
maintenance of cell membrane permeability and fluidity. There is
increasing evidence in support of the hypothesis that alterations in
cholesterol levels influence the development of AD by affecting A
formation and distribution within cholesterol rich membranes.
Proteolytic processing of APP is believed to occur at or in close
proximity to the cholesterol-rich plasma membrane. When cul-
tured human cells transfected with the APP cDNA are exposed to
an inhibitor of the HMG-CoA reductase (the rate controlling
enzyme of the metabolic pathway that produces cholesterol and
other isoprenoids) -secretase cleavage of newly synthesized APP
is markedly reduced. Addition of solubilized cholesterol to these
cells causes a four-fold increase in newly synthesized -amyloido-
genic products, while reduction of the cellular cholesterol level of
hippocampal neurons inhibits formation of A [110].
Above in vitro data correlate well with both in vivo experiments
using AD animal models and ex vivo data obtained from post-
mortem brains of AD patients. In a double transgenic mouse that
overexpresses mutant APP and presenilin-1, a high cholesterol
diet resulted in significantly increased levels of A in brain tissue.
The number and size of A deposits were elevated. Levels of total
A were strongly correlated with the levels of both plasma and
CNS cholesterol [111]. When these mice were treated with an
inhibitor of HMG CoA reductase, a cholesterol-lowering drug,
plasma cholesterol, brain A peptidesand A load decreased by
more than two-fold [112]. Results in cholesterol-fed rabbit mod-
els are consistent with these results in murine transgenic models.
Cholesterol-fed rabbits produce and accumulate A in the brain
and this accumulation can be reversed by removing cholesterol
from the rabbits’ diet [113, 114]. In post-mortem brains of AD
patients, fluorometric staining has confirmed cholesterol accumu-
lation in the core of mature senile plaques. Although it is not firmly
established whether disruption of cholesterol balance at the cellular
level is a primary cause of AD or rather a secondary effect of the dis-
order, the above evidence strongly support the view that membrane
cholesterol is responsible for the binding and toxicity of A.
Viral infections
Although the exact mechanisms of driving neuronal death by viral
infection are not very clear, it was proposed that string inflamma-
tory responses promoted by viral infections might be responsible
for the increased risk of developing AD. A comparative examination
of post-mortem brain tissue from 97 people with HIV/AIDS and
125 non-infected people of similar age established that A plaques,
indicative of AD, generally increased with age in both groups, but
were more than twice as common in the HIV/AIDS group. Almost
one in five of those who had died of AIDS in their 40s had the char-
acteristic plaques but there was no evidence these plaques in the
brain tissue of non-infected people of the same age. Two out of the
ten HIV infected patients in their late 30s and early 40s who had
died before developing AIDS also had the characteristic plaques.
These findings strongly indicated that an inflammatory response in
the brain, such as that caused by viral infection, may initiate and/or
accelerate the pathological processes leading to AD [115].
Actually, a number of viral or bacterial pathogens (Chlamydia
Pneumoniae, Herpes simplex type 1 (HSV-1) and type 2 (HSV-2),
herpes virus 6 (HHV-6), cytomegalovirus (CMV) and Helicobacter
pylori bacterium) have been implicated in AD [116–118]. As these
pathogens are so common, however, they probably only contribute
to AD if acting in concert with other factors, or under certain specific
conditions. It was shown that the risk-promoting effects of Herpes
simplex in AD are influenced by a number of molecular mechanisms
such as possession of the ApoE4 allele [119], APP processing [120],
and possible involvement of APP in the intraneuronal traffic of the
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virus [121]. Herpes infection was shown to increase the production
of A in mouse brains [122]. Numerous other genes and proteins
implicated in AD interact with the products of the Herpes simplex
viral genome or play a role in its life cycle, suggesting a complex syn-
ergy between host and pathogen that may play an important role in
the pathophysiology of AD (reviewed in [3]).
Interrelationship between different 
aetiopathogenic theories of AD
Many possible risk factors for AD have been investigated, with
only very few showing positive associations and none defining 
the aetiology of the neurodegenerative disease on its own.
Therefore, it is likely that interplay between at least some of these
potential risk factors determines AD pathogenesis via a patho-
physiological cascade.
Substantial evidence suggests that, apart from age, a history of
head injury [123–127] and/or certain types of viral infections
[128–131] increase the risk of AD. These two risk factors, however,
are accompanied by a chronic inflammatory reaction leading to the
release of a number of cytokines, including interferon (IFN)- and
TNF-. An inhibitory effect of IFN- on the translational machinery
has been well-documented [132–134], leading to lower expression
of proteins, including SC35 and hnRNPA1, whose downmodulation
results in increased secretion of A by cultured neurons [135]. A
cytokine-dependent enhancement of A production from APP-
expressing astrocytes and cortical neurons in transgenic mice was
also demonstrated [136]. Furthermore, HSV-1 protein ICP27 has
been shown to inhibit host cell splicing [137–139] by altering phos-
phorylation of SC35 and other proteins [140], which we showed to
yield in accumulation of A [135]. Cholesterol and other ‘raft’ lipid
components, such as sphingomyelin and galactosylceramide,
induce aggregation of the secreted A peptide [141, 142].The accu-
mulated amyloid plaques on the other hand cause neuronal death by
triggering a number of processes such as generation of ROS and
RNS and inhibition of proteasomes, but one of the most important
mechanisms is the activation of the complement system that not
only lyses neurons, but also generates inflammation which in turn
amplifies the AD risk factors. Due to the exceptionally complex
events involved in AD neurodegeneration and their reciprocal rela-
tionship and interaction, it is difficult to determine what the primary
cause of the disease is. It is likely that different primary risk factors
synergize to initiate pathology. It is also possible that several differ-
ent initial pathomechanisms ultimately result in a similar neu-
ropathology (plaques, tangles) and clinical phenomenology
(dementia), thus raising the question whether the diagnosis of AD
really represents a single nosological entity.
Treatment approaches
AD is a very complex disease and its clinical management is highly
challenging. Personality and behavioural changes, and the pro-
gressive difficulties with performing activities of daily living lead to
dependence on external help and support. A cure for AD is still not
available and clinicians and caregivers are challenged by an
increasingly aging population with ever higher risk of dementia.
The primary goals of treatment are to maximize the patient’s abil-
ity to function in daily life, maintain quality of life, slow the pro-
gression of symptoms, treat depression and disruptive behaviour.
However, at present all treatments for AD offer only modest symp-
tomatic relief for periods of between six to eighteen months. Some
of the currently used/researched agents are considered to delay or
even prevent AD symptoms which could contribute to reducing
the number of patient with dementia. However, until now comple-
ment proteins and CRegs have been overlooked as targets for the
development of neuroprotective drugs for AD treatment. But accu-
mulated data suggest that appropriate modulation of expression
and/or activity of proteins controlling the complement cascade
could be very beneficial for AD patients. Here we review the cur-
rent, albeit still unsatisfactory state of this field. There are a num-
ber of different categories of drugs currently used in AD treatment
(summarized in Table 1) and examples of each group are dis-
cussed below. Based on the ongoing research we also speculate
on the future developments regarding AD therapeutics.
Drugs which modify AD symptoms
Cholinergic treatment
Acetylcholinesterase inhibitors are one of the most commonly
used drugs to treat AD [143]. Their use stems from the observa-
tion that there is a deficiency in cholinergic neurotransmission in
AD. According to one hypothesis, decreased cholinergic transmis-
sion plays a major role in the development of cognitive, functional
and behavioural symptoms of AD [144, 145]. As a result of the
pathological changes during AD there are decreases in biochemical
indices of cholinergic functioning in neocortex and hippocampus
that correlate with dementia severity [146–148]. The hypothesis is
further supported by pharmacological studies using cholinergic
agonists and antagonists and transgenic animal models that
emphasize the close connection between cognition and choliner-
gic neurotransmission [149]. The cholinesterase inhibitors cur-
rently approved by the US Food and Drug Administration (FDA)
are tacrine, donepezil, rivastigmine and galantamine. The mecha-
nism of action of these drugs consists in increasing the availability
of acetylcholine through an inhibition of the catabolic enzyme
acetylcholinesterase.
Antiglutamic treatment
Another approach is to block glutamic neurotransmission.
Glutamate is the main excitatory neurotransmitter in the brain and
has been implicated in so-called excitotoxicity. One of its receptors –
M-methyl-D-aspartate (NMDA), has been implicated in long-term
potentiation, the neuronal mechanism responsible for learning and
memory [150]. The low affinity non-competitive NMDA antago-
nist, Memantine, was approved by the FDA for AD treatment in
© 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
4336 © 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Table 1. Therapeutics in use or under research/development for treatment of AD [255–258]
Agents Targets/mechanisms Status
Disease-modifying therapies
Donepezil (Aricepts) Cholinesterase inhibitor FDA approved
Rivastigmine (Exelon) Cholinesterase inhibitor FDA approved
Galantamine (Reminyl) Cholinesterase inhibitor FDA approved
Physostigmine Salicylate (Synapton) Acetylcholinesterase inhibitor Discontinued
Milameline (CI 979) Partial muscarinic agonist; Increases central cholinergic activity Discontinued
AF 102B (cevimeline HCL, Evoxac) Blocks production of A by increasing the activity of -secretase and possibly by
inhibiting -secretase
Discontinued
SB202026 (Memric, Sabcomeline) Selective muscarinic M1 partial agonist Discontinued
Tacrine (Cognex) Acetylcholinesterase inhibitor FDA approved
Metrifonate Cholinesterase inhibitor Discontinued
Memantine (Ebix, Namenda) NMDA receptor antagonist FDA approved
LY450139 -secretase inhibitor Phase III
PF-04494700 (TTP488) Inhibitor of Receptor for Advanced Glycation Endproducts (RAGE) Phase II/IIa/IIb
NGX267 (AF267B) M1 muscarinic agonist, -secretase activator Discontinued
AZD3480 (ispronicline, TC-1734) Nicotinic agonist with high selectivity for neuronal 42 nicotinic (nAChR) receptors Phase II/IIa/IIb
BMS-708163 -secretase inhibitor Phase II/IIa/IIb
AL-108 Stabilizes microtubules, blocks A aggregation Phase II
MK 0752 -secretase inhibitor Phase II
E2012 -secretase inhibitor Phase I
AZD103
ATG-Z1
Inhibits A fibrillization and disassembles preformed amyloid fibrils Phase I
Preclinical
OM99-2 BACE1 inhibitor Investigational
KMI-429 Analogue for the aspartyle protease, BACE1 inhibitor Investigational
GRL-8234 Analogue for the aspartyle protease, BACE1 inhibitor Investigational
KNI-1027 BACE1 inhibitor Investigational
GSK188909 BACE1 inhibitor Investigational
BACE1 inhibitor
Symptom-management therapies
Alpha-tocopherol (Vitamin E) Phase III
Acetyl-l-carnitine HCI (ALCAR) Destroys toxic free radicals
Not exactly known (some hypotheses: mitochondrial/energy 
Discontinued
Cerebrolysin
production; stabilizes membranes; decrease accumulations of toxic fatty acids)
FDA approved
(outside USA)
Ibuprofen Exerts nerve growth factor like activity on neurons from dorsal root ganglia; 
neurotrophic and neuroprotective agent
Phase III
Flurizan (MPC-7869, r-flurbiprofen) Reduces prostaglandin activity by inhibiting prostaglandin Discontinued
Huperzine 
(Cerebra capsule, Pharmassure)
synthetase; anti-inflammatory, analgesic ,and some antipyretic activity
Selective amyloid-lowering agent
Phase II/IIa/IIb
Discontinued
Naproxen (Aleve, Anaprox, Naprosyn)
Estrogen (Premarin)
Selective inhibition of AChE; alterations in APP processing; reduction of neurotoxicity
by A; antioxidant effects; increase of NGF production
Phase III
Phase III
Xaliproden Anti-inflammatory Phase III
Continued
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Agents Targets/mechanisms Status
Lecozotan
Dimebon
Thought to enhance growth of neurons in the basal forebrain; may have a
direct effect on A
5-HT1a receptor agonist
Phase III
Phase II/IIa/IIb
PRX-03410 5-HT1a receptor antagonist Phase II/IIa/IIb
MEM 1003
MEM 3454 (RO5313534)
Inhibitor of cholinesterase and NMDA receptors; Inhibits neuronal death,
potentially by mitochondrial-mediated inhibition of apoptosis
Partial 5-HT4 receptor agonist
Phase II/IIa/IIb
Phase II/IIa/IIb
CERE-110 (Nerve Growth Factor Gene Therapy) Neuronal L-type calcium channel antagonist
Selective nicotinic alpha-7 receptor partial agonist; 5-HT3 receptor antagonist
Inhibitors of complement system
Naturally occurring
Trophic agent in the survival and maintenance of basal forebrain cholinergic
neurons
Polyphenolic flavonoids Investigational
-glycyrrhetinic acid steroid-like Investigational
Polysaccharides (GR-2II, AGIIb-, BR-5I, AR-2IIa) Investigational
Sulfated polysaccharide (fucan) C3/C5-convertase inhibitors
Inhibitor of Classical pathway
Investigational
Esters (rosmarinic acid) In vitro inhibition of complement cascade at different stages Investigational
Polyanionic carbohydrates Investigational
Alkaloids
Ca2-binding polymers
Inhibit the classical pathway by interfering with C1 activation or by inhibiting
C3 cleavage
Investigational
Investigational
Glycoproteins (CI, CVF) C3/C5-convertase inhibitors Investigational
Peptide-like related to glycopeptide antibiotics
(complestatin)
Inhibitors of classical and alternative pathways
Inhibitors of classical pathway
Investigational
Fungal metabolite K-76 Inhibitors of classical pathway Investigational
Proteoglycans (decorin) C3-convertase inhibitors Investigational
Glycosaminoglycans (heparin) Inhibitors of classical and alternative pathways Investigational
Chondroitin sulphate proteoglycan (GCRF, CSPG) Inhibitors of classical and alternative pathways Investigational
C4-binding protein (C4bp) C1q inhibitor Investigational
Cyclic hexadepsipeptides C3-convertase inhibitor
C3bBb, factor B, C1q inhibitors
Investigational
Synthetic inhibitors Investigational
Peptide analogues and derivatives C4 inactivation in vitro and in vivo
(C089, PR226, CBP2, compstatin, etc.) C5aR antagonist in vitro and in vivo Investigational
Diisopropyl fluorophosphates (DFP, BCX-1470) C5aR or C3aR antagonists, bind to either C3, factor D, factor B or C1q Investigational
K-76 analogues (TKIXc, K-76COOH) Investigational
Nafamstat mesilate (FUT-175) Investigational
Oligodeoxyribonucleotide containing 
phosphorothioate (PS-oligo)
Factor D binding Investigational
Triterpenoid oleanolic acid derivatives Inhibitors of classical and alternative pathways Investigational
Inhibitory prodrug proteins (CD55- and 
CD59-prodrugs)
Inhibitors of classical and alternative pathways
Inhibitors of classical and alternative pathways
C3-convertase inhibitor
Inhibition of C3/C5-convertases or membrane attack complex (MAC)
Table 1 Continued
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2004. Memantine acts by blocking the NMDA receptor, thus pre-
venting calcium influx when neuronal firing rates are high, but
leaves the calcium channel open for transmission at low stimula-
tion rates [151]. Clinical studies demonstrate that the drug has
rather symptomatic benefits for patients than a disease modifying
effect [152, 153].
- and -secretase inhibitors
 and  secretases are the two enzymes critically responsible for
the formation of amyloid plaques (Fig. 1). Therefore, based on the
amyloid hypothesis, drugs that can prevent production, aggrega-
tion and deposition of A are thought to be promising therapeu-
tics for AD. In particular, the amyloidogenic pathway in neurons is
initiated by -secretase cleavage. The elucidation of the molecular
identity of -secretase, also called BACE1 (-site APP cleaving
enzyme 1) had been one of the key issues for the development of
AD therapeutics. Animal experiments showed that mice lacking 
-secretase are fertile, do not produce A42 and have no obvious
neurological deficits [154]. Clinical data support this approach
since activity of -secretase increases with age [155].
Development of -secretase inhibitors (BSI), however, has proven
to be challenging and to date none has been tested extensively in
human beings [156]. The crystal structure of BACE1 shows that
the active site is comprised a long cleft for substrate recognition
[157]. The structural features of BACE1 are used for design of BSI.
The first generation of BSI were designed as transition-state ana-
logues for the aspartyle protease (e.g. OM99–2, KMI-429). The
majority of commercially available potent BSI are peptide-based
compounds containing a transition-state moiety (e.g. hydroxyeth-
ylene, statin, etc.). Promising recent data suggest that KMI-429,
has great potential as it significantly reduced production and accu-
mulation of senile plaques in vivo in brains of wild-type and trans-
genic mice [158]. A new generation of BSI was designed recently
[159], containing hydroxyethylamine isostere and isophthalamide
moiety (GRL-8234). This compound efficiently inhibits BACE1
activity not only in vitro but also in vivo. Another recently gener-
ated BSI containing a 2,6-pyridinedicarboxylyc, chelidamic or che-
lidonic residue at the P2 position together with hydroxymethylcar-
bonyl isostere (KNI-1027) was also shown to inhibit efficiently
BACE1 [160]. Considering the usage of BSI as drugs, making less
peptidic compounds is mandatory to obtain sufficient oral absorp-
tion and penetration through the blood-brain barrier. These two
issues have hampered progress in development of BSI for AD
therapeutics, however, recently was generated the first orally
bioactive non-peptidic BSI, GSK188909, able to reduce brain A
levels in APP transgenic mice [161].
Although -secretase has in many ways been an attractive tar-
get for AD therapeutics, interference with Notch processing and
signalling may lead to toxicities that preclude clinical use of
inhibitors of this protease. Knockout of Notch1 or PS1 is embry-
onic-lethal in mice [162, 163] but Notch signalling and -secre-
tase activity are crucial in adulthood as well, because Notch plays
a critical role in many cell differentiation events [164]. Indeed,
treatment of mice with -secretase inhibitor (GSI) LY-411575 at
10 mg/kg/day for 15 days caused severe gastrointestinal toxicity
and, at 10 mg/kg/day, also interfered with the maturation of B and
T lymphocytes, effects that are due to inhibition of Notch process-
ing and signalling [165, 166]. The related compound, benzolactam
LY-450139, is two orders of magnitude less potent compared to
LY-411575; however, this compound has moved into clinical trials,
and so far it is the only GSI for which human trials have been
reported. LY-450139 was chronically administered for 5 months to
young APP transgenic mice, leading to reduced total brain A and
slower formation of A plaques. In initial human trials in healthy
volunteers [167] single doses of this GSI of up to 140 mg were
apparently safe and reduced plasma A levels by up to three quar-
ters. However, steady-state A in the CSF was not affected, and it
is unclear if higher doses can lower brain A without Notch-
related side effects. Sulphonamide inhibitor BMS-299897 was
developed to be selective for inhibiting the processing of APP over
Notch [168, 169], although the use of different assays in this
study does not allow simple comparisons. Single oral administra-
tion of this compound into APP transgenic mice gave an ED50
value of 30 mg/kg for lowering brain A and 16 mg/kg for lower
plasma A at 3 hrs after dosing. Intraperitoneal administration in
guinea pigs, which naturally produce high levels of A that is iden-
tical in sequence to the human peptide, reduced brain, plasma and
CSF A with an ED50 of 30 mg/kg at 3 hrs after dosing.
The hope of using GSI for treatment of AD is tempered by the
fact that -secretase cleaves numerous other type I membrane
protein stubs that result from ectodomain shedding [170]. Agents
selective for APP versus Notch may reveal new long-term toxici-
ties due to blocking proteolysis of these other substrates, toxici-
ties masked by the severe Notch-related effects with non-selective
inhibitors. To address this important issue, the development of
more potent agents that work by this mechanism will be critical.
Further detailed analysis of design and therapeutic potential of BSI
and GSI could be found in recently published reviews [171, 172]
dedicated specifically to this issue.
Drugs which potentially prevent and modify 
AD symptoms
Vitamins and antioxidants
Growing evidence supporting the oxidative stress hypothesis has
led to the concept of using antioxidants such as vitamin E (-toco-
pherol) as a potential treatment approach in AD. However, vitamin
E in combination with selegiline, a drug used for the treatment of
early-stage Parkinson’s disease, depression and senile dementia,
showed no real benefits for the patients [82]. Other clinical trials
also failed to show beneficial effects of vitamin E administration to
AD patients [173–175]. These results together with recent obser-
vations that high doses of vitamin E (400 IU/day) may increase
mortality [176] suggest that vitamin E should not be given as an
additive to other therapeutic approaches for AD treatment. Clinical
results for selegeline treatment have been rather controversial
suggesting either only a small benefit or no significant improve-
ment in the cognition of AD patients [177].
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The extract of the plant Ginkgo biloba was suggested to
enhance cognition. In addition to putative antioxidant properties,
the extract has been reported to reduce the aggregation of the A
peptide. However, in a randomized trial Ginkgo biloba did not sig-
nificantly enhance memory in healthy elderly adults [178].
Non-steroidal anti-inflammatory drugs
Retrospective observational studies have shown that the use of
NSAIDs may have protective properties regarding the develop-
ment of AD [10, 179–182]. In epidemiological studies, the use of
NSAIDs was associated with lower risk of developing AD and the
benefits seem to be greater with long-term use [179]. However,
NSAIDs only seem to offer protection if used before disease onset,
treatment after the development of AD symptoms results in little
or no benefit to the patients [183–187]. Therefore, currently
NSAIDs are not used in the treatment of AD.
Oestrogen replacement therapy
Women have two- to three-fold higher age-specific prevalence
rates of AD [188]. Women are oestrogen deficient after
menopause, whereas men rather maintain hormone levels as
testosterone undergoes aromatization to estradiol. Oestrogen is
considered to have a number of beneficial features such as antiox-
idant and anti-inflammatory properties, interactions with neuro-
transmitters such as acetylcholine, and an ability to alter
apolipoprotein which could lower the risk of developing AD. 
In vivo studies with low doses of conjugated oestrogen (Premarin)
in a rat model showed that this treatment can prevent vascular
deposition of A, thus protecting the endothelial cell from toxic
effects of the plaques [188, 189]. An anti-inflammatory effect of
the Premarin has also been demonstrated.
Inhibitors of complement-mediated degeneration
Recently we reviewed in detail the important dual role of the com-
plement system and its regulators in brain inflammation and neu-
ronal damage in AD [17]. This dual role should be carefully con-
sidered when choosing therapeutic targets for AD treatment. Until
now, complement proteins and CRegs have been largely over-
looked as targets for developing AD drugs, but accumulated data
suggest that appropriate modulation of expression and/or activity
of proteins controlling the complement cascade could be of great
clinical benefit for AD patients.
Cobra venom factor (CVF)
The earliest indication that inhibition of complement might be of
therapeutic benefit came from analyses of the effects of decomple-
mentation with CVF [190–194]. CVF binds mammalian fB in
plasma resulting in cleavage of fB by fD and production of C3 con-
vertase [195]. This process leads to consumption of all plasma C3
and lack of functional complement. However, after a week treat-
ment with CVF, experimental animals develop neutralising antibod-
ies against CVF which makes it ineffective for longer-term thera-
peutic applications, e.g. in AD. Nevertheless, CVF has provided a
useful proof-of-concept for the theory that complement activation
is of relevance in diverse neuropathologies.
Heparin and other polyionic agents
Heparin, a polyanionic glycosaminoglycan, has long been recog-
nized as an in vitro inhibitor of complement [196]. Heparin affects
complement activation at multiple levels, by binding and inactivat-
ing C1, blocking generation of the C3 convertases and interfering
with the assembly of MAC [197–200]. Very few studies have
addressed the potential use of heparin as a complement inhibitor
in vivo. N-acetylated heparin with much reduced anticoagulant
activity can inhibit CVF-induced complement activation in guinea
pigs [201]. Further in vitro work on human samples demonstrated
that heparins were much more efficient inhibitors in human than
in guinea pig serum [202]. Interestingly, it was recently demon-
strated that this drug can interfere with the metabolism of amyloid
plaques and reduces the accumulation of A [203]. Long-term
treatment with enoxaparin, a low molecular weight heparin, in
human APP751 transgenic mice can significantly reduce the dep-
osition of amyloid plaques and A aggregation [203]. Chronic
treatment with enoxaparin is well tolerated and does not increase
side effects such as haemorrhage in the brain. Although the exact
mechanism is not yet clear, a reduced ability of A to activate
complement system and its classical pathway may play a role.
Numerous related and unrelated polyanionic molecules,
including dextran sulphate, polyvinyl sulphate, polylysine and
suramin, inhibit complement activation in vitro (reviewed in
[204]). However, their applicability in vivo and particularly for
treatment of AD has not been investigated.
Other small molecule inhibitors
Many synthetic and natural molecules have been shown to inhibit
complement activation in vitro. A few natural inhibitors have
shown efficient complement inhibition both in vitro and in animal
models. The molecule termed K-76COOH, isolated from cultures
of the fungus Stachybotrys complementi, inhibits complement at
the C5 stage [205, 206]. Rosmarinic acid, extracted from the com-
mon shrub Rosemary, covalently binds activated C3b and pre-
vents formation of the convertase [207, 208]. An extract of the
Chinese medicinal herb, Ephedra, inhibits complement at multiple
levels including the terminal pathway [209]. Among the synthetic
complement inhibitors, the protease inhibitor FUT-175 is one of
the best investigated. It inhibits C1r, C1s, fD and the C3/C5 con-
vertases [210, 211]. FUT-175 is effective in numerous animal
models of complement-mediated disease [212, 213], although it
has not been studied in AD models. Some success has also been
obtained using small molecules, such as peptides, that bind active
sites of complement components or enzymes and prevent their
participation in the cascade. Examples of such peptides are C089,
PR226, CBP2 and compstatin. The use of the small molecule
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inhibitors, however, is currently hampered by non-specific side
effects or short half-life [214] and therefore, none of them are
likely to be useful for therapy of chronic diseases such as AD
unless these problems can be solved.
Recombinant protein inhibitors
In addition to the approaches described above, a plethora of solu-
ble therapeutics has been developed which specifically inhibit the
complement cascade [215]. Early agents were based on the natu-
rally occurring membrane-associated CRegs, such as CD49, CD59
and Complement Receptor 1(CR1; CD35). Removal of membrane-
anchoring domains using recombinant technology generated sol-
uble molecules with the same regulatory functions as the ‘parent’
inhibitor which could be administered locally or systemically to
inhibit complement. The best known of these is a soluble form of
CR1 (sCR1), an agent developed nearly 30 years ago and used in
the clinic, with limited success, for complement inhibition in
myocardial infarction (MI) and cardiopulmonary bypass (CPB)
[216–218]. These ‘first-generation’ agents have been engineered
and modified over the years to improve characteristics such as
half-life (by introducing antibody Fc domains) [219], membrane
localisation (by using lipid ‘tails’) [220] and specific targeting of
complement activation sites (by using fusion proteins comprising
a domain that binds C3 activation fragments, thus localising to the
site of C attack) [221]. Some success has also been obtained
using small molecules, such as peptides, that bind active sites of
complement components or enzymes and prevent their participa-
tion in the cascade. Their use, however, is hampered by non-
 specific side effects or short half-life [214]. Perhaps the most suc-
cessful soluble therapeutic agents have been antibody-based
agents, such as full-length immunoglobulin of single-chain Fv
(scFv) fragments. Antibodies that bind C5, thereby preventing trig-
gering of the terminal pathway and MAC formation, have been
successfully used in the treatment of various pathologies exacer-
bated by complement activation. Anti-C5 in particular is used for
treatment of paroxysmal nocturnal haemoglobinuria, MI and
arthritis [222–224].
The problem however with many of these agents is that their
action is systemic, totally blocking the complement cascade. In
addition, if they are targeting the alternative, classical or MBL acti-
vation pathways, their long-term use can be detrimental, trigger-
ing immune complex disease and permitting bacterial infections
as the key functions of complement in innate immunity are pre-
vented. In the case of AD, it may be beneficial to selectively inhibit
parts of the complement cascade. For example, inhibition of the
terminal pathway using antibodies that allow C5a formation but
prevent MAC formation may prevent neuronal damage but still
permit the observed protective effects of C5a. Another agent,
developed to selectively inhibit MAC formation, but which will still
allow C5a generation, is a CD59-Ig fusion protein [225]. This has
been tested in a murine model of laser-induced choroidal neovas-
cularization and shown to have therapeutic effects. CD59-Ig,
which is a long-lived agent, halts the complement cascade at the
level of C8. Agents that specifically target complement inhibition
to the vicinity of the amyloid plaques would avoid systemic inhibi-
tion of C, and provide enhanced protection to neurons. Previous
in vitro studies have demonstrated that recombinant techniques
can be used to fuse CReg to the carboxy-termini of antibodies or
antibody fragments, thus locating the therapeutic action of the
inhibitor to the site pre-determined by antibody specificity [226].
If recombinant antibodies to A, or other antigens unique to the
plaque, are developed, then specific targeting of CD59 or other
substrates at sites of disease may be possible. It is clear that the
exact role of each complement component in AD is yet to be
understood (see Complement-mediated neurodegeneration sec-
tion). Only then, specifically targeted anti-complement agents will
be likely to be developed and to be of therapeutic benefit. Testing
prototype agents in murine models of AD, or further investigation
of the role of complement in the disease using component-
 deficient animals will help clarify the potential of anti-complement
therapy in AD.
Anti-amyloid therapy (‘vaccination’)
The major aim of anti-amyloid therapy is to induce clearance of the
amyloid plaques, one of the defining risk factors and pathological
hallmarks of AD. A largely unexpected discovery showed that
immunization with A42 peptide prevents the appearance of amy-
loid pathology in a transgenic mouse model of AD [227]. Follow-
up studies confirmed this finding in other models of the disease
[228]. These experiments suggested that passive immunization
with antibodies against human A should decrease the neuritic
plaques and this hypothesis was confirmed in transgenic mice,
including improved performance in behavioural tests [229, 230].
Further to these promising experiments in animal-models without
apparent side effects, clinical trials with a vaccine designated as
AN1792 containing pre-aggregated A42 and QS21 as an adju-
vant were carried out. The design of this vaccine aimed to induce
a strong cell-mediated immune response, since QS21 is a strong
inducer of Th1 pro-inflammatory lymphocytes [231]. This initial
trial involved 80 patients with mild to moderate AD [232] and was
design to assess the antigenicity and toxicity of multiple immuni-
sations with A42 peptide containing QS21. Slightly more than
half of the patients (53%) developed antibodies against A.
During the later stages of the phase I trial, the emulsifier polysor-
bate 80 was added to the vaccine, shifting the response from a
predominantly Th2 biased to a pro-inflammatory Th1 [233]. In the
subsequent phase II trial, 372 patients were enrolled with 300
receiving AN1792 in the polysorbate 80 formulation.
Unfortunately, this trial had to be stopped prematurely after 6% of
patients (18 out of 298 subjects) who received the vaccine devel-
oped acute meningoencephalitis [234]. Nevertheless, the trial and
ex vivo studies yielded some important data. Striking A clearance
of parenchymal plaques had occurred, similar to what had been
reported in the animal studies, confirming the validity of this
approach for amyloid clearance in human beings [235–239].
Antibodies raised by this active immunisation were specific for
senile plaques only and did not cross-react with the full-length
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APP or other derivates [240]. Furthermore, neuropathological
evaluation suggested involvement of activated microglia in plaque
clearance [239, 241]. Another interesting observation suggested a
mechanism for the observed A plaque clearance, which actively
involves complement system. C1q enhances the uptake of anti-
body-fibrillar A complexes in vitro by microglia, possibly via
C1qRp receptor [242]. Despite the striking A clearance, several
significant problems were apparent from the pathological and clin-
ical data from these trials. Some of the pathologically examined
cases showed a harmful T-cell reaction surrounding cerebral ves-
sels, suggesting an excessive Th1 immune response. It appeared
that the immune reaction triggered by the AN1792 vaccine was a
double-edge sward, where the benefits of a humoural response
against A42 were surpassed in some individuals by a detrimen-
tal Th1-mediated inflammatory response [235, 243]. Furthermore,
despite the apparent success in amyloid clearance, the clinical
cognitive benefits from the vaccination were very modest com-
pared to the placebo group [244, 245]. The above observations
suggest a possibly promising future for passive or active immuni-
sation against amyloid plaques. However, further studies on opti-
mal time to begin immunisation, design of improved vaccines and
pre-clinical models, determination of most appropriate target for
vaccination (detail discussed in [246]) are mandatory. A combina-
tion of anti-amyloid therapy with anti-inflammatory therapeutics
might be a solution to overcome currently existing problems such
as devastating side effects (meningoencephalitis). However,
whether such a combination would be beneficial for AD patients
needs to be addressed in further empirical studies, after its safety
has been confirmed.
Another interesting approach is to prevent cleavage of APP in the
first place by blocking the cleavage site of -secretases and thus
formation of A [247]. Antibodies that block APP cleavage by -
secretase were tested in an in vitro model in which cells expressed
wild-type APP. These antibodies bound full-length APP, internalized
it into the cells and inhibited both intra- and extracellular A peptide
formation. The same antibody has also been tested in a transgenic
mouse model expressing human APP. The animals showed
improved cognitive functions and a reduction in brain inflammation
as well as in the incidence of microhaemorrhage. Interestingly,
these beneficial effects were not associated with the levels of A
which were unaltered by antibody treatment [247]. Therefore, the
exact mechanism by which this antibody induced these improve-
ments in transgenic animals, remains to be elucidated.
Targeting proteasome inhibition
As proteasome inhibition may play a contributing role to neurode-
generation, it is important to determine mechanisms which may
modulate that inhibition. One obvious target for proteasome inhi-
bition could be an efficient up-regulation of the levels of HSPs
within the CNS. Increasing the concentration of molecules of the
HSP family should help to preserve proteasome activity and pos-
sibly result in delaying age-related proteasome inhibition.
Alternatively, pharmacological interventions designed to stimulate
proteasome activity within the CNS may provide some therapeutic
benefit. Different studies have identified a number of pharmaco-
logical proteasome activators that may ultimately provide the
basis for such treatments in the future [248–250]. Furthermore, a
strategy increasing the expression of specific proteasome sub-
units might also be useful for the protection of neurons. A novel
protein has been identified in yeast that is responsible for the tran-
scription of a number of proteasome subunits [251]. Although no
mammalian homologue has yet been found, these data raise the
possibility of utilizing such a protein to elevate potentially benefi-
cial levels of proteasome expression in the CNS of human beings.
The importance of the proteasome in CNS physiology and
pathology is only beginning to emerge. It is likely that future
studies on this intriguing enzyme will yield further important
information, particularly on the regulation of protein turnover in
the CNS. Ultimately, this may lead to designing of new and use-
ful AD therapeutics.
Neuropeptide mixture (Cerebrolysin)
Cerebrolysin (CBL) is an anti-inflammatory mixture of neuropep-
tides (smaller than 10kDa) obtained from porcine brain tissue
[252]. Due to its complexity, this therapeutic targets different
mechanisms causing neuronal death. It exhibits unique neu-
rotrophic and neuroprotective activity and reduces amyloid bur-
den in animal models. It also improves neurodegenerative alter-
ations in an APP model of AD [253]. CBL regulates the activity of
cyclin-dependant kinase-5 and glycogen synthases kinase 3,
which phosphorylate APP, thus reducing levels of phosphorylated
APP and accumulation of APP in neuritic processes [252]. This in
turn reduces the level of available APP for cleavage by the secre-
tases. Studies in patients with mild to moderate AD have shown
that CBL improves cognitive performance [254]. In addition to the
neuroprotective mechanisms described above, we have recently
demonstrated that CBL can also protect of neurons from comple-
ment-mediated degeneration via increasing expression of CD59
and CD55 membrane-bound CReg, while expression of CD46
remains unaffected (unpublished data). Therefore, CBL has a mul-
tilevel effect on neurons possessing anti-inflammatory, anti-apop-
totic, neurotrophic and neuroprotective properties, while at the
same time inducing local inhibition of complement on neuronal
surfaces. Further well-designed experiments are urgently needed
to further assess the beneficial properties of CBL in AD, as well as
its potential in other neuropsychiatric disorders.
Conclusions
Multiple approaches to understand the pathogenesis of AD have
unravelled the mechanisms of neuronal death in AD. A and
inflammation risk factors are considered to be the principal play-
ers in AD pathogenesis. Inflammation, A and other AD-related
© 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
References
1. Tana S. Alzheimer’s disease – opportuni-
ties to address pharmaceutical gaps. In:
Kaplan W, Laing R, editors. Priority medi-
cines for Europe and the world – A public
health approach to innovation. Geneva
(Switzerland): World Health Organization;
2004. pp. 3–6.
2. Bertram L, McQueen M, Mullin K, et al.
Systematic meta-analyses of Alzheimer dis-
ease genetic association studies: the AlzGene
database. Nat Genet. 2007; 39: 17–23.
3. Carter C. Convergence of genes implicated
in Alzheimer’s disease on the cerebral cho-
lesterol shuttle: APP, cholesterol, lipopro-
teins, and atherosclerosis. Neurochem Int.
2007; 50: 12–38.
4. Selkoe D. Alzheimer’s disease results from
the cerebral accumulation and cytotoxicity
of amyloid beta-protein. J Alzheimers Dis.
2001; 3: 75–80.
5. Prasad K, Cole W, Prasad K. Risk factors
for Alzheimer’s disease: role of multiple
antioxidants, non-steroidal anti-inflamma-
tory and cholinergic agents alone or in
combination in prevention and treatment.
J Am Coll Nutr. 2002; 21: 506–22.
6. Rich J, Rasmusson D, Folstein M, et al.
Nonsteroidal anti-inflammatory drugs in
Alzheimer’s disease. Neurology. 1995; 45:
51–5.
7. Akiyama H, Barger S, Barnum S, et al.
Inflammation and Alzheimer’s disease.
Neurobiol Aging. 2000; 21: 383–421.
8. Bradt B, Kolb W, Cooper N. Complement-
dependent proinflammatory properties of
the Alzheimer’s disease beta-peptide. J Exp
Med. 1998; 188: 431–8.
9. Breitner J, Welsh K, Helms M, et al.
Delayed onset of Alzheimer’s disease with
nonsteroidal anti-inflammatory and hista-
mine H2 blocking drugs. Neurobiol Aging.
1995; 16: 523–30.
10. Breitner J, Gau B, Welsh K, et al. Inverse
association of anti-inflammatory treat-
ments and Alzheimer’s disease: initial
results of a co-twin control study.
Neurology. 1994; 44: 227–32.
11. Andersen K, Launer L, Ott A, et al. Do
nonsteroidal anti-inflammatory drugs
decrease the risk for Alzheimer’s disease?
The Rotterdam Study. Neurology. 1995;
45: 1441–5.
12. Myllykangas-Luosujärvi R, Isomäki H.
Alzheimer’s disease and rheumatoid arthri-
tis. Br J Rheumatol. 1994; 33: 501–2.
13. McGeer P, Schulzer M, McGeer E.
Arthritis and anti-inflammatory agents as
possible protective factors for Alzheimer’s
disease: A review of 17 epidemiologic
studies. Neurology. 1996; 47: 425–32.
14. Rogers J, Kirby L, Hempelman S,
et al. Clinical trial of indomethacin in
Alzheimer’s disease. Neurology. 1993; 43:
1609–11.
15. Sharif S, Hariri R, Chang V, et al. Human
astrocyte production of tumour necrosis
factor-alpha, interleukin-1 beta, and 
interleukin-6 following exposure to
lipopolysaccharide endotoxin. Neurol Res.
1993; 15: 109–12.
16. Shalit F, Sredni B, Stern L, et al. Elevated
interleukin-6 secretion levels by mononu-
clear cells of Alzheimer’s patients.
Neurosci Lett. 1994; 174: 130–2.
17. Kolev M, Ruseva M, Harris C, et al.
Implication of complement system and its
regulators in Alzheimer’s disease. Curr
Neuropharmacol. 2009; 7: 1–8.
18. Anderton B. Free radicals on the mind.
Hydrogen peroxide mediates amyloid beta
protein toxicity. Hum Exp Toxicol. 1994;
13: 716–9.
19. Chen L, Richardson J, Caldwell J, et al.
Regional brain activity of free radical
defense enzymes in autopsy samples from
patients with Alzheimer’s disease and from
nondemented controls. Int J Neurosci.
1994; 75: 83–90.
20. Rozemuller J, Eikelenboom P, Pals S,
et al. Microglial cells around amyloid
plaques in Alzheimers disease express
leukocyte adhesion molecules of the 
LFA-1 family. Neurosci Lett. 1989; 101:
288–92.
21. Verbeek M, Otteholler I, Westphal J,
et al. Accumulation of intercellular adhe-
sion molecule-1 in senile plaques in brain
tissue of patients with Alzheimers disease.
Am J Pathol. 1994; 144: 104–16.
22. Prasad K, Hovland A, La Rosa F, et al.
Prostaglandins as putative neurotoxins in
Alzheimer’s disease. Proc Soc Exp Biol
Med. 1998; 219: 120–5.
23. Lue L, Rydel R, Brigham E, et al.
Inflammatory repertoire of Alzheimer’s
disease and nondemented elderly microglia
in vitro. Glia. 2001; 35: 72–9.
24. Smits H, Rijsmus A, van Loon J, et al.
Amyloid-beta-induced chemokine produc-
tion in primary human macrophages and
astrocytes. J Neuroimmunol. 2002; 127:
160–8.
25. Heneka M, Galea E, Gavriluyk V, et al.
Noradrenergic depletion potentiates beta -
amyloid-induced cortical inflammation:
implications for Alzheimer’s disease. 
J Neurosci. 2002; 22: 2434–42.
4342
pathological changes induce various types of toxic mechanisms
that contribute to neuronal death. This indicates the complex
nature of AD pathogenesis. Prevention and blockage of these
mechanisms is critical for the palliative and curative therapy of AD.
The advances in understanding the cellular, molecular and genetic
mechanisms underlying the aetiopathogenesis of the disease lead
to the identification of various potential therapeutic targets. The
need for effective treatment is urgent, since current drugs for
treating the cognitive impairments in AD are based on neurotrans-
mitter replacement or modulation, which produce only mild symp-
tomatic benefit with minimal impact on the disease process and
causality. However, some very promising new strategies for fight-
ing AD have been proposed including anti-amyloid treatment; and
CBL, which protects neurons by simultaneously acting on a num-
ber of mechanisms involved in neuronal death (anti-amyloid, anti-
inflammatory, anti-apoptotic, inhibition of complement system,
neuroprotective, neurotrophic, etc). Due to the disease complex-
ity, it is likely that therapeutics that aim against multiple targets
will result in a more efficient management of AD and might also be
effective in various forms of AD with different underlying patho-
physiological mechanisms. Therefore, further extensive experi-
mental studies, in vitro and in vivo are urgently needed.
Acknowledgements
We thank Claire Harris and B. Paul Morgan for helpful comments and dis-
cussions. R.D. was supported by the Medical Research Council, UK New
Investigator Award Grant G0700102.
© 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
J. Cell. Mol. Med. Vol 13, No 11-12, 2009
4343
26. Joachim C, Selkoe D. The seminal role of
beta-amyloid in the pathogenesis of
Alzheimer disease. Alzheimer Dis Assoc
Disord. 1992; 6: 7–34.
27. Selkoe D. Cell biology of the amyloid beta-
protein precursor and the mechanism of
Alzheimer’s disease. Annu Rev Cell Biol.
1994; 10: 373–403.
28. Wang G, Khatoon S, Iqbal K, et al. Brain
ubiquitin is markedly elevated in Alzheimer
disease. Brain Res. 1991; 566: 146–51.
29. Kudo T, Iqbal K, Ravid R, et al. Alzheimer
disease: correlation of cerebro-spinal fluid
and brain ubiquitin levels. Brain Res. 1994;
639: 1–7.
30. Checler F, da Costa C, Ancolio K, et al.
Role of the proteasome in Alzheimer’s dis-
ease. Biochim Biophys Acta. 2000; 1502:
133–8.
31. Rockwell P, Yuan H, Magnusson R, et al.
Proteasome inhibition in neuronal cells
induces a proinflammatory response man-
ifested by upregulation of cyclooxygenase-
2, its accumulation as ubiquitin conju-
gates, and production of the prostaglandin
PGE(2). Arch Biochem Biophys. 2000;
374: 325–33.
32. Gregori L, Hainfeld J, Simon M, et al.
Binding of amyloid beta protein to the 20 S
proteasome. J Biol Chem. 1997; 272:
58–62.
33. Mackenzie I. Anti-inflammatory drugs and
Alzheimer-type pathology in aging.
Neurology. 2000; 54: 732–4.
34. Weggen S, Eriksen J, Das P, et al. A sub-
set of NSAIDs lower amyloidogenic
Abeta42 independently of cyclooxygenase
activity. Nature. 2001; 414: 212–6.
35. Bate C, Veerhuis R, Eikelenboom P, et al.
Neurones treated with cyclo-oxygenase-1
inhibitors are resistant to amyloid-beta1–42.
Neuroreport. 2003; 14: 2099–103.
36. Shaftel S, Griffin W, O’Banion M. The role
of interleukin-1 in neuroinflammation and
Alzheimer disease: an evolving perspec-
tive. J Neuroinflammation. DOI: 10.1186/
1742-2094-5-7.
37. Oprica M, Hjorth E, Spulber S, et al.
Studies on brain volume, Alzheimer-
related proteins and cytokines in mice with
chronic overexpression of IL-1 receptor
antagonist. J Cell Mol Med. 2007; 11:
810–25.
38. Selkoe D, Schenk D. Alzheimer’s disease:
Molecular understanding predicts amy-
loid-based therapeutics. Annu Rev
Pharmacol Toxicol. 2003; 43: 545–84.
39. Morishima M, Ihara Y. Posttranslational
modifications of tau in paired helical fila-
ments. Dementia. 1994; 5: 282–8.
40. Caughey B, Lansbury P. Protofibrils,
pores, fibrils, and neurodegeneration:
Separating the responsible protein aggre-
gates from the innocent bystanders. Annu
Rev Neurosci. 2003; 26: 267–98.
41. Gschwind M, Huber G. Apoptotic cell
death induced by beta-amyloid(1–42) pep-
tide is cell type dependent. J Neurochem.
1995; 65: 292–300.
42. Vincent B, Cisse M, Sunyach C, et al.
Regulation of betaAPP and PrPc cleavage
by alpha-secretase: mechanistic and thera-
peutic perspectives. Curr Alzheimer Res.
2008; 5: 202–11.
43. Brunkan A, Goate A. Presenilin function
and gamma-secretase activity. J Neurochem.
2005; 93: 769–92.
44. Wolfe M, Xia W, Ostaszewski B, et al.
Two transmembrane aspartates in prese-
nilin-1 required for presenilin endoproteol-
ysis and gamma-secretase activity. Nature.
1999; 398: 513–7.
45. De Strooper B. Aph-1, Pen-2, and
Nicastrin with Presenilin generate an active
gamma-Secretase complex. Neuron. 2003;
38: 9–12.
46. Haass C. Take five–BACE and the gamma-
secretase quartet conduct Alzheimer’s
amyloid beta-peptide generation. EMBO J.
2004; 23: 483–8.
47. Borchelt D, Thinakaran G, Eckman C,
et al. Familial Alzheimer’s disease-linked
presenilin 1 variants elevate Abeta1–42/1–40
ratio in vitro and in vivo. Neuron. 1996; 17:
1005–13.
48. Rogaev E, Sherrington R, Rogaeva E,
et al. Familial Alzheimer’s disease in kin-
dreds with missense mutations in a gene
on chromosome 1 related to the
Alzheimer’s disease type 3 gene. Nature.
1995; 376: 775–8.
49. Scheuner D, Eckman C, Jensen M,, et al.
Secreted amyloid beta-protein similar to
that in the senile plaques of Alzheimer’s
disease is increased in vivo by the prese-
nilin 1 and 2 and APP mutations linked to
familial Alzheimer’s disease. Nat Med.
1996; 2: 864–70.
50. De Strooper B, Saftig P, Craessaerts K,
et al. Deficiency of presenilin-1 inhibits
the normal cleavage of amyloid precursor
protein. Nature. 1998; 391: 387–90.
51. Mastrangelo P, Mathews P, Chishti M,
et al. Dissociated phenotypes in presenilin
transgenic mice define functionally distinct
gamma-secretases. Proc Natl Acad Sci
USA. 2005; 102: 8972–7.
52. Popescu B, Ankarcrona M. Neurons bear-
ing presenilins: weapons for defense or
suicide? J Cell Mol Med. 2000; 4: 249–61.
53. Cowburn R, Popescu B, Ankarcrona M,
et al. Presenilin-mediated signal transduc-
tion. Physiol Behav. 2007; 92: 93–7.
54. Canevari L, Abramov A, Duchen M.
Toxicity of amyloid beta peptide: Tales of
calcium, mitochondria, and oxidative
stress. Neurochem Res. 2004; 29: 637–50.
55. LaFerla F. Calcium dyshomeostasis and
intracellular signalling in Alzheimer’s dis-
ease. Nat Rev Neurosci. 2002; 3: 862–72.
56. Morishima Y, Gotoh Y, Zieg J, et al. beta-
amyloid induces neuronal apoptosis via a
mechanism that involves the c-Jun N-ter-
minal kinase pathway and the induction of
Fas ligand. J Neurosci. 2001; 21: 7551–60.
57. Lee M, Kwon Y, Li M, et al. Neurotoxicity
induces cleavage of p35 to p25 by calpain.
Nature. 2000; 405: 360–4.
58. Bozyczko-Coyne D, O’Kane T, Wu Z, et al.
CEP-1347/KT-7515, an inhibitor of
SAPK/JNK pathway activation, promotes
survival and blocks multiple events associ-
ated with A beta-induced cortical neuron
apoptosis. J Neurochem. 2001; 77:
849–63.
59. Morishima-Kawashima M, Oshima N,
Ogata H, et al. Effect of apolipoprotein E
allele epsilon 4 on the initial phase of amy-
loid beta-protein accumulation in the
human brain. Am J Pathol. 2000; 157:
2093–9.
60. Mucke L, Masliah E, Yu G, et al. High-
level neuronal expression of A beta(1–42)
in wild-type human amyloid protein pre-
cursor transgenic mice: Synaptotoxicity
without plaque formation. J Neurosci.
2000; 20: 4050–8.
61. Lue L, Kuo Y, Roher A, et al. Soluble 
amyloid beta peptide concentration as 
a predictor of synaptic change in
Alzheimer’s disease. Am J Pathol. 1999;
155: 853–62.
62. Walsh D, Lomakin A, Benedek G, et al.
Amyloid beta-protein fibrillogenesis –
Detection of a protofibrillar intermediate. 
J Biol Chem. 1997; 272: 22364–72.
63. Lambert M, Barlow A, Chromy B, et al.
Diffusible, nonfibrillar ligands derived from
Abeta1–42 are potent central nervous sys-
tem neurotoxins. Proc Natl Acad Sci USA.
1998; 95: 6448–53.
64. Wang H, Pasternak J, Kuo H, et al.
Soluble oligomers of beta amyloid (1–42)
inhibit long-term potentiation but not long-
term depression in rat dentate gyrus. Brain
Res. 2002; 924: 133–40.
65. Klein W. Abeta toxicity in Alzheimer’s dis-
ease: globular oligomers (ADDLs) as new
vaccine and drug targets. Neurochem Int.
2002; 41: 345–52.
© 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
4344
66. Shankar G, Li S, Mehta T, et al. Amyloid-
beta protein dimers isolated directly from
Alzheimer’s brains impair synaptic plastic-
ity and memory. Nat Med. 2008; 14:
837–42.
67. Naylor R, Hill A, Barnham K. Is covalently
crosslinked Abeta responsible for synapto-
toxicity in Alzheimer’s disease? Curr
Alzheimer Res. 2008; 5: 533–9.
68. Asghar S, Pasch M. Therapeutic inhibition
of the complement system. Y2K update.
Front Biosci. 2000; 5: E63–81.
69. Silva C, Rio M, Cruz C. Local
immunoglobulin synthesis and blood-
brain barrier assessment in subacute scle-
rosing panencephalitis. Eur Neurol. 1985;
24: 128–33.
70. Barnum S. Complement biosynthesis in
the central nervous system. Crit Rev Oral
Biol Med. 1995; 6: 132–46.
71. Emmerling MR, Watson MD, Raby CA,
et al. The role of complement in
Alzheimer’s disease pathology. Bichemica
et Biophysica Acta. 2000; 1502: 158–71.
72. Gasque P, Fontaine M, Morgan B.
Complement expression in human brain –
biosynthesis of terminal pathway compo-
nents and regulators in human glial cells
and cell lines. J Immunol. 1995; 154:
4726–33.
73. Vedeler C, Ulvestad E, Bjorge L, et al.
The expression of CD59 in normal human
nervos tissue. Immunol. 1994; 82: 542–7.
74. Pasinetti G, Johnson S, Oda T, et al.
Clusterin (SGP-2) – a multifunctional gly-
coprotein with regional expression in
astrocytes and neurons of the adult rat
brain. J Comp Neurol. 1994; 339:
387–400.
75. Yang L, Li R, Meri S, Rogers J, et al.
Deficiency of complement defense protein
CD59 may contribute to neurodegenera-
tion in Alzheimer’s disease. J Neurosci.
2000; 20: 7505–9.
76. Osaka H, Mukherjee P, Aisen P, et al.
Complement-derived anaphylatoxin C5a
protects against glutamate-mediated neu-
rotoxicity. J Cell Biochem. 1999; 73:
303–11.
77. Pasinetti G. Inflammatory mechanisms in
neurodegeneration and Alzheimer’s dis-
ease: the role of the complement system.
Neurobiol Aging. 1996; 17: 707–16.
78. Wyss-Coray T, Yan F, Lin A, et al.
Prominent neurodegeneration and
increased plaque formation in comple-
ment-inhibited Alzheimer’s mice. Proc
Natl Acad Sci USA. 2002; 99: 10837–42.
79. Pisalyaput K, Tenner A. Complement
component C1q inhibits beta-amyloid- and
serum amyloid P-induced neurotoxicity via
caspase- and calpain-independent mecha-
nisms. J Neurochem. 2008; 104: 696–707.
80. Maier M, Peng Y, Jiang L, et al.
Complement C3 deficiency leads to accel-
erated amyloid beta plaque deposition and
neurodegeneration and modulation of the
microglia/macrophage phenotype in amy-
loid precursor protein transgenic mice. 
J Neurosci. 2008; 28: 6333–41.
81. Gasque P, Thomas A, Fontaine M, et al.
Complement activation on human neurob-
lastoma cell lines in vitro: route of activa-
tion and expression of functional comple-
ment regulatory proteins. J Neuroimmunol.
1996; 66: 29–40.
82. Sano M, Ernesto C, Thomas R, et al. A
controlled trial of selegiline, alpha-toco-
pherol, or both as treatment for
Alzheimer’s disease. The Alzheimer’s
Disease Cooperative Study. N Engl J Med.
1997; 336: 1216–22.
83. Birkmayer J. Coenzyme nicotinamide ade-
nine dinucleotide: new therapeutic
approach for improving dementia of the
Alzheimer type. Ann Clin Lab Sci. 1996;
26: 1–9.
84. Misonou H, Morishima-Kawashima M,
et al. Oxidative stress induces intracellular
accumulation of amyloid beta-protein (A
beta) in human neuroblastoma cells.
Biochemistry. 2000; 39: 6951–9.
85. Koppaka V, Axelsen P. Accelerated accu-
mulation of amyloid beta proteins on
oxidatively damaged lipid membranes.
Biochemistry. 2000; 39: 10011–6.
86. Schubert D, Behl C, Lesley R, et al.
Amyloid peptides are toxic via a common
oxidative mechanism. Proc Natl Acad Sci
USA. 1995; 92: 1989–93.
87. Behl C, Davis J, Cole G, et al. Vitamin E
protects nerve cells from amyloid beta
protein toxicity. Biochem Biophys Res
Commun. 1992; 186: 944–50.
88. Zaman Z, Roche S, Fielden P, et al.
Plasma concentrations of vitamin E and
carotenoids in Alzheimers disease. Age
Ageing. 1992; 21: 91–4.
89. Sims N, Bowen D, Neary D, et al.
Metabolic processes in Alzheimers disease
adenine nucleotide content and production
of (CO2)-C-14 from [U-C-14] glucose 
in vitro in human neocortex. J Neurochem.
1983; 41: 1329–34.
90. Saito K, Elce J, Hamos J, et al.
Widespread activation of calcium-activated
neutral proteinase (calpain) in the brain in
Alzheimer disease – a potential molecular
basis for neuronal degeneration. Proc Natl
Acad Sci USA. 1993; 90: 2628–32.
91. Zhou Y, Richardson J, Mombourquette
M, et al. Free radical formation in autopsy
samples of Alzheimer and control cortex.
Neurosci Lett. 1995; 195: 89–92.
92. Simic G, Lucassen P, Krsnik Z, et al.
nNOS expression in reactive astrocytes
correlates with increased cell death related
DNA damage in the hippocampus and
entorhinal cortex in Alzheimer’s disease.
Exp Neurol. 2000; 165: 12–26.
93. Conrad C, Marshall P, Talent J, et al.
Oxidized proteins in Alzheimer’s plasma.
Biochem Biophys Res Commun. 2000;
275: 678–81.
94. Keller J, Markesbery W. Proteasome inhi-
bition results in increased poly-ADP-ribo-
sylation: Implications for neuron death. 
J Neurosci Res. 2000; 61: 436–42.
95. Qiu J, Asai A, Chi S, et al. Proteasome
inhibitors induce cytochrome c-caspase-3-
like protease-mediated apoptosis in cul-
tured cortical neurons. J Neurosci. 2000;
20: 259–65.
96. Pasquini L, Moreno M, Adamo A, et al.
Lactacystin, a specific inhibitor of the pro-
teasome, induces apoptosis and activates
caspase-3 in cultured cerebellar granule
cells. J Neurosci Res. 2000; 59: 601–11.
97. Wagenknecht B, Hermisson M, Groscurth
P, et al. Proteasome inhibitor-induced
apoptosis of glioma cells involves the pro-
cessing of multiple caspases and
cytochrome c release. J Neurochem. 2000;
75: 2288–97.
98. Taglialatela G, Kaufmann J, Trevino A,
et al. Central nervous system DNA frag-
mentation induced by the inhibition of
nuclear factor kappa B. Neuroreport. 1998;
9: 489–93.
99. Kitagawa H, Tani E, Ikemoto H, et al.
Proteasome inhibitors induce mitochon-
dria-independent apoptosis in human
glioma cells. FEBS Lett. 1999; 443: 181–6.
100. Marambaud P, Chevallier N, Barelli H,
et al. Proteasome contributes to the
alpha-secretase pathway of amyloid 
precursor protein in human cells. 
J Neurochem. 1997; 68: 698–703.
101. Skovronsky D, Pijak D, Doms R, et al. A
distinct ER/IC gamma-secretase competes
with the proteasome for cleavage of APP.
Biochemistry. 2000; 39: 810–7.
102. Honda T, Yasutake K, Nihonmatsu N,
et al. Dual roles of proteasome in the
metabolism of presenilin 1. J Neurochem.
1999; 72: 255–61.
103. Ingano L, Lentini K, Kovacs I, et al.
Cytoplasmic presenilin aggregates in pro-
teasome inhibitor-treated cells. Mol Basis
Dementia. 2000; 920: 259–60.
© 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
J. Cell. Mol. Med. Vol 13, No 11-12, 2009
4345
104. Kwak S, Masaki T, Ishiura S, et al.
Multicatalytic proteinase is present in
Lewy bodies and neurofibrillary tangles in
diffuse Lewy body disease brains.
Neurosci Lett. 1991; 128: 21–4.
105. Masaki T, Ishiura S, Sugita H, et al.
Multicatalytic proteinsase is associated
with characteristic oval structures in corti-
cal Lewy bodies – an immunocytochemical
study with light and electron microscopy.
J Neurol Sci. 1994; 122: 127–34.
106. Canu N, Barbato C, Ciotti M, et al.
Proteasome involvement and accumula-
tion of ubiquitinated proteins in cerebellar
granule neurons undergoing apoptosis. 
J Neurosci. 2000; 20: 589–99.
107. Favit A, Grimaldi M, Alkon D. Prevention
of beta-amyloid neurotoxicity by blockade
of the ubiquitin-proteasome proteolytic
pathway. J Neurochem. 2000; 75: 1258–63.
108. Grilli M, Memo M. Possible role of NF-
kappa B and p53 in the glutamate-induced
pro-apoptotic neuronal pathway. Cell
Death Differ. 1999; 6: 22–7.
109. Mattson M, Culmsee C, Yu Z, et al. Roles
of nuclear factor kappa B in neuronal sur-
vival and plasticity. J Neurochem. 2000;
74: 443–56.
110. Simons M, Keller P, De Strooper B, et al.
Cholesterol depletion inhibits the genera-
tion of beta-amyloid in hippocampal neu-
rons. Proc Natl Acad Sci USA. 1998; 95:
6460–4.
111. Refolo L, Pappolla M, Malester B, et al.
Hypercholesterolemia accelerates the
Alzheimer’s amyloid pathology in a trans-
genic mouse model. Neurobiol Disease.
2000; 7: 321–31.
112. Refolo L, Pappolla M, LaFrancois J,
et al. A cholesterol-lowering drug reduces
beta-amyloid pathology in a transgenic
mouse model of Alzheimer’s disease.
Neurobiol Disease. 2001; 8: 890–9.
113. Sparks D, Scheff S, Hunsaker J, et al.
Induction of Alzheimer-like -amyloid
immunoreactivity in the brains of rabbits
with dietary cholesterol. Exp Neurol. 1994;
126: 88–94.
114. Sparks D. Intraneuronal beta-amyloid
immunoreactivity in the CNS. Neurobiol
Aging. 1996; 17: 291–9.
115. Esiri M, Biddolph S, Morris C. Prevalence
of Alzheimer plaques in AIDS. J Neurol
Neurosurg Psychiatry. 1998; 65: 29–33.
116. Kountouras J, Tsolaki M, Gavalas E,
et al. Relationship between Helicobacter
pylori infection and Alzheimer disease.
Neurology. 2006; 66: 938–40.
117. Itzhaki R, Wozniak M, Appelt D, et al.
Infiltration of the brain by pathogens
causes Alzheimer’s disease. Neurobiol
Aging. 2004; 25: 619–27.
118. Ball M. The essential lesion of Alzheimer
disease: a surprise in retrospect. 
J Alzheimers Dis. 2006; 9: 29–33.
119. Itzhaki R, Wozniak M. Herpes simplex
virus type 1, apolipoprotein E, and choles-
terol: a dangerous liaison in Alzheimer’s
disease and other disorders. Prog Lipid
Res. 2006; 45: 73–90.
120. Shipley S, Parkin E, Itzhaki R, et al.
Herpes simplex virus interferes with amy-
loid precursor protein processing. BMC
Microbiol. DOI: 10.1186/1471-2180-5-48.
121. Satpute-Krishnan P, DeGiorgis J, et al.
Fast anterograde transport of herpes sim-
plex virus: role for the amyloid precursor
protein of Alzheimer’s disease. Aging Cell.
2003; 2: 305–18.
122. Wozniak M, Itzhaki R, Shipley S, et al.
Herpes simplex virus infection causes cel-
lular beta-amyloid accumulation and sec-
retase upregulation. Neurosci Lett. 2007;
429: 95–100.
123. Heyman A, Wilkinson W, Stafford J,
et al. Alzheimer’s disease: a study of epi-
demiological aspects. Ann Neurol. 1984;
15: 335–41.
124. French L, Schuman L, Mortimer J, et al.
A case-control study of dementia of the
Alzheimer type. Am J Epidemiol. 1985;
121: 414–21.
125. Mortimer J, van Duijn C, Chandra V,
et al. Head trauma as a risk factor for
Alzheimer’s disease: a collaborative re-
analysis of case-control studies. EURO-
DEM Risk Factors Research Group. Int J
Epidemiol. 1991; 20: S28–35.
126. Schofield P, Tang M, Marder K, et al.
Alzheimer’s disease after remote head
injury: an incidence study. J Neurol
Neurosurg Psychiatry. 1997; 62: 119–24.
127. Yamada M, Sasaki H, Mimori Y, et al.
Prevalence and risks of dementia in the
Japanese population: RERF’s adult health
study Hiroshima subjects. Radiation
Effects Research Foundation. J Am Geriatr
Soc. 1999; 47: 189–95.
128. Jamieson G, Maitland N, Wilcock G,
et al. Latent herpes simplex virus type 1 in
normal and Alzheimer’s disease brains. 
J Med Virol. 1991; 33: 224–7.
129. Lin W, Shang D, Itzhaki R. Neurotropic
viruses and Alzheimer disease. Interaction
of herpes simplex type 1 virus and
apolipoprotein E in the etiology of the dis-
ease. Mol Chem Neuropathol. 1996; 28:
135–41.
130. Langenberg A, Corey L, Ashley R, et al.
A prospective study of new infections with
herpes simplex virus type 1 and type 2.
Chiron HSV Vaccine Study Group. N Engl
J Med. 1999; 341: 1432–8.
131. Hill J, Steiner I, Matthews K, et al.
Statins lower the risk of developing
Alzheimer’s disease by limiting lipid raft
endocytosis and decreasing the neuronal
spread of Herpes simplex virus type 1.
Med Hypotheses. 2005; 64: 53–8.
132. Petryshyn R, Chen J, Danley L, et al.
Effect of interferon on protein translation
during growth stages of 3T3 cells. Arch
Biochem Biophys. 1996; 326: 290–7.
133. Hiremath M, Mikhael A, Taylor L, et al.
Complex regulation of the Csk homolo-
gous kinase (Chk) by IL-4 family cytokines
and IFN-gamma in human peripheral blood
monocytes. Mol Immunol. 2004; 41: 901–10.
134. Donev RM, Cole DS, Sivasankar B, et al.
p53 regulates cellular resistance to com-
plement lysis through enhanced expression
of CD59. Cancer Res. 2006; 66: 2451–8.
135. Donev R, Newall A, Thome J, et al. A role
for SC35 and hnRNPA1 in the determina-
tion of amyloid precursor protein iso-
forms. Mol Psychiatry. 2007; 12: 681–90.
136. Yamamoto M, Kiyota T, Horiba M, et al.
Interferon-gamma and tumor necrosis fac-
tor-alpha regulate amyloid-beta plaque
deposition and beta-secretase expression
in Swedish mutant APP transgenic mice.
Am J Pathol. 2007; 170: 680–92.
137. Hardwicke M, Sandri-Goldin R. The her-
pes simplex virus regulatory protein ICP27
contributes to the decrease in cellular
mRNA levels during infection. J Virol.
1994; 68: 4797–810.
138. Bryant H, Wadd S, Lamond A, et al.
Herpes simplex virus IE63 (ICP27) protein
interacts with spliceosome-associated
protein 145 and inhibits splicing prior to
the first catalytic step. J Virol. 2001; 75:
4376–85.
139. Lindberg A, Kreivi J. Splicing inhibition at
the level of spliceosome assembly in the
presence of herpes simplex virus protein
ICP27. Virology. 2002; 294: 189–98.
140. Sciabica K, Dai Q, Sandri-Goldin R.
ICP27 interacts with SRPK1 to mediate
HSV splicing inhibition by altering SR pro-
tein phosphorylation. EMBO J. 2003; 22:
1608–19.
141. Klajnert B, Cortijo-Arellano M, Cladera J,
et al. Influence of dendrimer’s structure
on its activity against amyloid fibril forma-
tion. Biochem Biophys Res Commun.
2006; 345: 21–8.
142. Yanagisawa K. Cholesterol and amyloid
beta fibrillogenesis. Subcell Biochem.
2005; 38: 179–202.
© 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
4346
143. Cummings J. Alzheimer’s disease. N Engl
J Med. 2004; 351: 56–67.
144. Francis P, Palmer A, Snape M, et al. The
cholinergic hypothesis of Alzheimer’s dis-
ease: a review of progress. J Neurol
Neurosurg Psychiatry. 1999; 66: 137–47.
145. Cummings J, Kaufer D. Neuropsychiatric
aspects of Alzheimer’s disease: the cholin-
ergic hypothesis revisited. Neurology.
1996; 47: 876–83.
146. Perry E, Gibson P, Blessed G, et al.
Neurotransmitter enzyme abnormalities in
senile dementia. Choline acetyltransferase
and glutamic acid decarboxylase activities
in necropsy brain tissue. J Neurol Sci.
1977; 34: 247–65.
147. Wilcock G, Esiri M, Bowen D, et al.
Alzheimer’s disease. Correlation of cortical
choline acetyltransferase activity with the
severity of dementia and histological
abnormalities. J Neurol Sci. 1982; 57:
407–17.
148. Perry E, Tomlinson B, Blessed G, et al.
Correlation of cholinergic abnormalities
with senile plaques and mental test scores
in senile dementia. Br Med J. 1978; 2:
1457–9.
149. Wilkinson D, Francis P, Schwam E, et al.
Cholinesterase inhibitors used in the treat-
ment of Alzheimer’s disease: the relation-
ship between pharmacological effects and
clinical efficacy. Drugs Aging. 2004; 21:
453–78.
150. Katsuki H, Izumi Y, Zorumski C. Removal
of extracellular calcium after conditioning
stimulation disrupts long-term potentia-
tion in the CA1 region of rat hippocampal
slices. Neuroscience. 1997; 76: 1113–9.
151. Lipton S. Failures and successes of NMDA
receptor antagonists: molecular basis for
the use of open-channel blockers like
memantine in the treatment of acute and
chronic neurologic insults. NeuroRx.
2004; 1: 101–10.
152. Reisberg B, Doody R, Stöffler A, et al.
Memantine in moderate-to-severe
Alzheimer’s disease. N Engl J Med. 2003;
348: 1333–41.
153. Winblad B, Poritis N. Memantine in
severe dementia: results of the 9M-Best
Study (Benefit and efficacy in severely
demented patients during treatment with
memantine). Int J Geriatr Psychiatry.
1999; 14: 135–46.
154. Roberds S, Anderson J, Basi G, et al.
BACE knockout mice are healthy despite
lacking the primary beta-secretase activity
in brain: implications for Alzheimer’s dis-
ease therapeutics. Hum Mol Genet. 2001;
10: 1317–24.
155. Fukumoto H, Rosene D, Moss M, et al.
Beta-secretase activity increases with
aging in human, monkey, and mouse
brain. Am J Pathol. 2004; 164: 719–25.
156. Leung D, Abbenante G, Fairlie D.
Protease inhibitors: current status and
future prospects. J Med Chem. 2000; 43:
305–41.
157. Hong L, Koelsch G, Lin X, et al. Structure
of the protease domain of memapsin 2
(beta-secretase) complexed with inhibitor.
Science. 2000; 290: 150–3.
158. Asai M, Hattori C, Iwata N, et al. The
novel beta-secretase inhibitor KMI-429
reduces amyloid beta peptide production
in amyloid precursor protein transgenic
and wild-type mice. J Neurochem. 2006;
96: 533–40.
159. Ghosh A, Kumaragurubaran N, Hong L,
et al. Potent memapsin 2 (beta-secretase)
inhibitors: design, synthesis, protein-lig-
and X-ray structure, and in vivo evaluation.
Bioorg Med Chem Lett. 2008; 18: 1031–6.
160. Hamada Y, Ohta H, Miyamoto N, et al.
Novel non-peptidic and small-sized BACE1
inhibitors. Bioorg Med Chem Lett. 2008;
18: 1643–7.
161. Hussain I, Hawkins J, Harrison D, et al.
Oral administration of a potent and selec-
tive non-peptidic BACE-1 inhibitor
decreases beta-cleavage of amyloid pre-
cursor protein and amyloid-beta produc-
tion in vivo. J Neurochem. 2007; 100:
802–9.
162. Wong P, Zheng H, Chen H, et al.
Presenilin 1 is required for Notch1 and
DII1 expression in the paraxial mesoderm.
Nature. 1997; 387: 288–92.
163. Shen J, Bronson R, Chen D, et al. Skeletal
and CNS defects in presenilin-1-deficient
mice. Cell. 1997; 89: 629–39.
164. Selkoe D, Kopan R. Notch and Presenilin:
regulated intramembrane proteolysis links
development and degeneration. Annu Rev
Neurosci. 2003; 26: 565–97.
165. Searfoss G, Jordan W, Calligaro D, et al.
Adipsin, a biomarker of gastrointestinal
toxicity mediated by a functional gamma-
secretase inhibitor. J Biol Chem. 2003;
278: 46107–16.
166. Wong G, Manfra D, Poulet F, et al. Chronic
treatment with the gamma-secretase
inhibitor LY-411,575 inhibits beta-amyloid
peptide production and alters lym-
phopoiesis and intestinal cell differentiation.
J Biol Chem. 2004; 279: 12876–82.
167. Siemers E, Quinn J, Kaye J, et al. Effects
of a gamma-secretase inhibitor in a ran-
domized study of patients with Alzheimer
disease. Neurology. 2006; 66: 602–4.
168. Barten D, Guss V, Corsa J, et al.
Dynamics of {beta}-amyloid reductions in
brain, cerebrospinal fluid, and plasma of
{beta}-amyloid precursor protein trans-
genic mice treated with a {gamma}-secre-
tase inhibitor. J Pharmacol Exp Ther. 2005;
312: 635–43.
169. Anderson J, Holtz G, Baskin P, et al.
Reductions in beta-amyloid concentrations
in vivo by the gamma-secretase inhibitors
BMS-289948 and BMS-299897. Biochem
Pharmacol. 2005; 69: 689–98.
170. Kopan R, Ilagan M. Gamma-secretase:
proteasome of the membrane? Nat Rev
Mol Cell Biol. 2004; 5: 499–504.
171. Wolfe M. Inhibition and modulation of
gamma-secretase for Alzheimer’s disease.
Neurotherapeutics. 2008; 5: 391–8.
172. Tomita T. Secretase inhibitors and 
modulators for Alzheimer’s disease treat-
ment. Expert Rev Neurother. 2009; 9:
661–79.
173. MRC/BHF. Heart Protection Study of
antioxidant vitamin supplementation in
20,536 high-risk individuals: a randomised
placebo-controlled trial. Lancet. 2002;
360: 23–33.
174. Luchsinger J, Tang M, Shea S, et al.
Antioxidant vitamin intake and risk of
Alzheimer disease. Arch Neurol. 2003; 60:
203–8.
175. Laurin D, Masaki K, Foley D, et al.
Midlife dietary intake of antioxidants and
risk of late-life incident dementia: the
Honolulu-Asia Aging Study. Am J
Epidemiol. 2004; 159: 959–67.
176. Miller Er, Pastor-Barriuso R, Dalal D.
Meta-analysis: high-dosage vitamin E sup-
plementation may increase all-cause mor-
tality. Ann Intern Med. 2005; 142: 37–46.
177. Cummings J. The role of cholinergic
agents in the management of behavioural
disturbances in Alzheimer’s disease. Int J
Neuropsychopharmacol. 2000; 3: 21–9.
178. Solomon P, Adams F, Silver A, et al.
Ginkgo for memory enhancement: a ran-
domized controlled trial. JAMA. 2002; 288:
835–40.
179. Etminan M, Gill S, Samii A. Effect of non-
steroidal anti-inflammatory drugs on risk
of Alzheimer’s disease: systematic review
and meta-analysis of observational stud-
ies. BMJ. 2003; 327: 128.
180. in t’ Veld B, Ruitenberg A, Hofman A,
et al. Nonsteroidal antiinflammatory drugs
and the risk of Alzheimer’s disease. N Engl
J Med. 2001; 345: 1515–21.
181. Zandi P, Anthony J, Hayden K, et al.
Reduced incidence of AD with NSAID but
not H2 receptor antagonists: the Cache
© 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
J. Cell. Mol. Med. Vol 13, No 11-12, 2009
4347
County Study. Neurology. 2002; 59:
880–6.
182. Beard C, Waring S, O’Brien P, et al.
Nonsteroidal anti-inflammatory drug use
and Alzheimer’s disease: a case-control
study in Rochester, Minnesota, 1980
through 1984. Mayo Clin Proc. 1998; 73:
951–5.
183. Aisen P, Schafer K, Grundman M, et al.
Effects of rofecoxib or naproxen vs
placebo on Alzheimer disease progression:
a randomized controlled trial. JAMA. 2003;
289: 2819–26.
184. Van Gool W, Weinstein H, Scheltens P,
et al. Effect of hydroxychloroquine on pro-
gression of dementia in early Alzheimer’s
disease: an 18-month randomised, 
double-blind, placebo-controlled study.
Lancet. 2001; 358: 455–60.
185. Aisen P. Anti-inflammatory therapy for
Alzheimer’s disease: implications of the
prednisone trial. Acta Neurol Scand Suppl.
2000; 176: 85–9.
186. Aisen P, Schmeidler J, Pasinetti G.
Randomized pilot study of nimesulide
treatment in Alzheimer’s disease.
Neurology. 2002; 58: 1050–4.
187. Scharf S, Mander A, Ugoni A, et al. A
double-blind, placebo-controlled trial of
diclofenac/misoprostol in Alzheimer’s dis-
ease. Neurology. 1999; 53: 197–201.
188. Thomas T, Rhodin J. Vascular actions of
estrogen and Alzheimer’s disease. Ann N Y
Acad Sci. 2000; 903: 501–9.
189. Koh K, Cardillo C, Bui M et al. Vascular
effects of estrogen and cholesterol-lower-
ing therapies in hypercholesterolemic
postmenopausal women. Circulation.
1999; 99: 354–60.
190. Gewurz H, Clark D, Cooper M, et al.
Effect of cobra venom-induced inhibition
of complement activity on allograft and
xenograft rejection reactions. Transplantation.
1967; 5: 1296–303.
191. Maillard J, Zarco R. [Decomplementization
by a factor extracted from cobra venom.
Effect on several immune reactions of the
guinea pig and rat]. Ann Inst Pasteur. 1968;
114: 756–74.
192. Cochrane C, Müller-Eberhard H, Aikin B.
Depletion of plasma complement in vivo
by a protein of cobra venom: its effect on
various immunologic reactions. J Immunol.
1970; 105: 55–69.
193. Phillips G. Studies on a hemolytic factor
of cobra venom requiring a heat-labile
serum factor. Biochim Biophys Acta. 1970;
201: 364–74.
194. Müller-Eberhard H, Fjellström K. Isolation
of the anticomplementary protein from
cobra venom and its mode of action on C3.
J Immunol. 1971; 107: 1666–72.
195. Cooper N. Formation and function of a
complex of the C3 proactivator with a pro-
tein from cobra venom. J Exp Med. 1973;
137: 451–60.
196. Weiler J, Yurt R, Fearon D, et al.
Modulation of the formation of the amplifi-
cation convertase of complement, C3b, Bb,
by native and commercial heparin. J Exp
Med. 1978; 147: 409–21.
197. Baker P, Lint T, McLeod B, et al. Studies
on the inhibition of C56-induced lysis
(reactive lysis). VI. Modulation of C56-
induced lysis polyanions and polycations.
J Immunol. 1975; 114: 554–8.
198. Hughes-Jones N, Gardner B. The reaction
between the complement subcomponent
C1q, IgG complexes and polyionic mole-
cules. Immunology. 1978; 34: 459–63.
199. Almeda S, Rosenberg R, Bing D. The
binding properties of human complement
component C1q. Interaction with
mucopolysaccharides. J Biol Chem. 1983;
258: 785–91.
200. Weiler J. Polyions regulate the alternative
amplification pathway of complement.
Immunopharmacology. 1983; 6: 245–55.
201. Weiler J, Edens R, Linhardt R, et al.
Heparin and modified heparin inhibit com-
plement activation in vivo. J Immunol.
1992; 148: 3210–5.
202. Edens R, Linhardt R, Bell C, et al.
Heparin and derivatized heparin inhibit
zymosan and cobra venom factor 
activation of complement in serum.
Immunopharmacology. 1994; 27: 145–53.
203. Bergamaschini L, Rossi E, Storini C,
et al. Peripheral treatment with enoxa-
parin, a low molecular weight heparin,
reduces plaques and beta-amyloid accu-
mulation in a mouse model of Alzheimer’s
disease. J Neurosci. 2004; 24: 4181–6.
204. Asghar S. Pharmacological manipulation
of complement system. Pharmacol Rev.
1984; 36: 223–44.
205. Hong K, Kinoshita T, Kitajima H, et al.
Inhibitory effect of K-76 monocarboxylic
acid, an anticomplementary agent, on the
C3b inactivator system. J Immunol. 1981;
127: 104–8.
206. Miyazaki W, Izawa T, Nakano Y, et al.
Effects of K-76 monocarboxylic acid, an
anticomplementary agent, on various 
in vivo immunological reactions and 
on experimental glomerulonephritis.
Complement. 1984; 1: 134–46.
207. Englberger W, Hadding U, Etschenberg
E, et al. Rosmarinic acid: a new inhibitor
of complement C3-convertase with 
anti-inflammatory activity. Int J
Immunopharmacol. 1988; 10: 729–37.
208. Sahu A, Rawal N, Pangburn M. Inhibition
of complement by covalent attachment of
rosmarinic acid to activated C3b. Biochem
Pharmacol. 1999; 57: 1439–46.
209. Ling M, Piddlesden S, Morgan B. A com-
ponent of the medicinal herb ephedra
blocks activation in the classical and alter-
native pathways of complement. Clin Exp
Immunol. 1995; 102: 582–8.
210. Fujii S, Hitomi Y. New synthetic inhibitors
of C1r, C1 esterase, thrombin, plasmin,
kallikrein and trypsin. Biochim Biophys
Acta. 1981; 661: 342–5.
211. Inagi R, Miyata T, Maeda K, et al. FUT-
175 as a potent inhibitor of C5/C3 conver-
tase activity for production of C5a and C3a.
Immunol Lett. 1991; 27: 49–52.
212. Ino Y, Sato T, Koshiyama Y, et al.
Effects of FUT-175, a novel synthetic pro-
tease inhibitor, on the development of adju-
vant arthritis in rats and some biological
reactions dependent on complement activa-
tion. Gen Pharmacol. 1987; 18: 513–6.
213. Miyagawa S, Shirakura R, Matsumiya G,
et al. Prolonging discordant xenograft
survival with anticomplement reagents
K76COOH and FUT175. Transplantation.
1993; 55: 709–13.
214. Holland M, Morikis D, Lambris J.
Synthetic small-molecule complement
inhibitors. Curr Opin Investig Drugs. 2004;
5: 1164–73.
215. Morgan B, Harris C. Complement thera-
peutics; history and current progress. Mol
Immunol. 2003; 40: 159–70.
216. Weisman H, Bartow T, Leppo M, et al.
Soluble human complement receptor 
type 1: in vivo inhibitor of complement
suppressing post-ischemic myocardial
inflammation and necrosis. Science. 1990;
249: 146–51.
217. Lazar H, Keilani T, Fitzgerald C, et al.
Beneficial effects of complement inhibition
with soluble complement receptor 1 (TP10)
during cardiac surgery: is there a gender
difference? Circulation. 2007; 116: I83–8.
218. Lazar H, Bokesch P, van Lenta F, et al.
Soluble human complement receptor 1
limits ischemic damage in cardiac surgery
patients at high risk requiring cardiopul-
monary bypass. Circulation. 2004; 110:
II274–9.
219. Harris C, Williams A, Linton S, et al.
Coupling complement regulators to
immunoglobulin domains generates 
effective anti-complement reagents with
extended half-life in vivo. Clin Exp
Immunol. 2002; 129: 198–207.
© 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
4348
220. Smith G, Smith R. Membrane-targeted
complement inhibitors. Mol Immunol.
2001; 38: 249–55.
221. Song H, He C, Knaak C, et al.
Complement receptor 2-mediated target-
ing of complement inhibitors to sites of
complement activation. J Clin Invest.
2003; 111: 1875–85.
222. Carrier M, Ménasché P, Levy J, et al.
Inhibition of complement activation by
pexelizumab reduces death in patients
undergoing combined aortic valve replace-
ment and coronary artery bypass surgery.
J Thorac Cardiovasc Surg. 2006; 131:
352–6.
223. Brodsky R, Young N, Antonioli E, et al.
Multicenter phase 3 study of the comple-
ment inhibitor eculizumab for the treat-
ment of patients with paroxysmal noctur-
nal hemoglobinuria. Blood. 2008; 111:
1840–7.
224. Kaplan M. Eculizumab (Alexion). Curr
Opin Investig Drugs. 2002; 3: 1017–23.
225. Bora N, Kaliappan S, Jha P, et al. CD59,
a complement regulatory protein, controls
choroidal neovascularization in a mouse
model of wet-type age-related macular
degeneration. J Immunol. 2007; 178:
1783–90.
226. Zhang H, Yu J, Bajwa E, et al. Targeting
of functional antibody-CD59 fusion pro-
teins to a cell surface. J Clin Invest. 1999;
103: 55–61.
227. Schenk D, Barbour R, Dunn W, et al.
Immunization with amyloid-beta attenu-
ates Alzheimer-disease-like pathology in
the PDAPP mouse. Nature. 1999; 400:
173–7.
228. Janus C, Pearson J, McLaurin J, et al. A
beta peptide immunization reduces behav-
ioural impairment and plaques in a model
of Alzheimer’s disease. Nature. 2000; 408:
979–82.
229. DeMattos R, Bales K, Cummins D, et al.
Peripheral anti-A beta antibody alters CNS
and plasma A beta clearance and
decreases brain A beta burden in a mouse
model of Alzheimer’s disease. Proc Natl
Acad Sci USA. 2001; 98: 8850–5.
230. Dodart J, Bales K, Gannon K, et al.
Immunization reverses memory deficits
without reducing brain Abeta burden in
Alzheimer’s disease model. Nat Neurosci.
2002; 5: 452–7.
231. Wisniewski T, Frangione B. Immunological
and anti-chaperone therapeutic approaches
for Alzheimer disease. Brain Pathol. 2005;
15: 72–7.
232. Bayer A, Bullock R, Jones R, et al.
Evaluation of the safety and immunogenic-
ity of synthetic Abeta42 (AN1792) in
patients with AD. Neurology. 2005; 64:
94–101.
233. Pride M, Seubert P, Grundman M, et al.
Progress in the active immunotherapeutic
approach to Alzheimer’s disease: clinical
investigations into AN1792-associated
meningoencephalitis. Neurodegener Dis.
2008; 5: 194–6.
234. Orgogozo J, Gilman S, Dartigues J, et al.
Subacute meningoencephalitis in a subset
of patients with AD after Abeta42 immu-
nization. Neurology. 2003; 61: 46–54.
235. Boche D, Nicoll J. The role of the immune
system in clearance of Abeta from the
brain. Brain Pathol. 2008; 18: 267–78.
236. Boche D, Zotova E, Weller R, et al.
Consequence of Abeta immunization on
the vasculature of human Alzheimer’s dis-
ease brain. Brain. 2008; 131: 3299–310.
237. Bombois S, Maurage C, Gompel M, et al.
Absence of beta-amyloid deposits after
immunization in Alzheimer disease with
Lewy body dementia. Arch Neurol. 2007;
64: 583–7.
238. Masliah E, Hansen L, Adame A, et al.
Abeta vaccination effects on plaque pathol-
ogy in the absence of encephalitis in
Alzheimer disease. Neurology. 2005; 64:
129–31.
239. Nicoll J, Barton E, Boche D, et al. Abeta
species removal after abeta42 immuniza-
tion. J Neuropathol Exp Neurol. 2006; 65:
1040–8.
240. Hock C, Konietzko U, Papassotiropoulos
A, et al. Generation of antibodies specific
for beta-amyloid by vaccination of patients
with Alzheimer disease. Nat Med. 2002; 8:
1270–5.
241. Nicoll J, Wilkinson D, Holmes C, et al.
Neuropathology of human Alzheimer dis-
ease after immunization with amyloid-beta
peptide: a case report. Nat Med. 2003; 9:
448–52.
242. Webster S, Galvan M, Ferran E, et al.
Antibody-mediated phagocytosis of the
amyloid beta-peptide in microglia is differ-
entially modulated by C1q. J Immunol.
2001; 166: 7496–503.
243. Sadowski M, Wisniewski T. Disease 
modifying approaches for Alzheimer’s
pathology. Curr Pharm Des. 2007; 13:
1943–54.
244. Gilman S, Koller M, Black R, et al.
Clinical effects of Abeta immunization
(AN1792) in patients with AD in an inter-
rupted trial. Neurology. 2005; 64: 1553–62.
245. Holmes C, Boche D, Wilkinson D, et al.
Long-term effects of Abeta42 immunisa-
tion in Alzheimer’s disease: follow-up of a
randomised, placebo-controlled phase I
trial. Lancet. 2008; 372: 216–23.
246. Wisniewski T. AD vaccines: conclusions
and future directions. CNS Neurol Disord
Drug Targets. 2009; 8: 160–6.
247. Rakover I, Arbel M, Solomon B.
Immunotherapy against APP beta-secre-
tase cleavage site improves cognitive func-
tion and reduces neuroinflammation in
Tg2576 mice without a significant effect
on brain abeta levels. Neurodegener Dis.
2007; 4: 392–402.
248. Wilk S, Chen W. Synthetic peptide-based
activators of the proteasome. Mol Biol
Rep. 1997; 24: 119–24.
249. Wilk S, Chen W, Magnusson R.
Modulation of the PA28 alpha-20S protea-
some interaction by a peptidyl alcohol.
Arch Biochem Biophys. 1999; 362:
283–90.
250. Demena I, Mahillo E, Arribas J, et al.
Kinetic mechanism of activation by cardi-
olipin (diphosphatidylglycerol) of the rat
liver multicatalytic proteinase. Biochem J.
1993; 296: 93–7.
251. Xie Y, Varshavsky A. RPN4 is a ligand,
substrate, and transcriptional regulator of
the 26S proteasome: A negative feedback
circuit. Proc Natl Acad Sci USA. 2001; 98:
3056–61.
252. Rockenstein E, Torrance M, Mante M,
et al. Cerebrolysin decreases amyloid-beta
production by regulating amyloid protein
precursor maturation in a transgenic
model of Alzheimer’s disease. J Neurosci
Res. 2006; 83: 1252–61.
253. Rockenstein E, Mallory M, Mante M,
et al. Effects of Cerebrolysin on amyloid-
beta deposition in a transgenic model of
Alzheimer’s disease. J Neural Transm
Suppl. 2002; 62: 327–36.
254. Rüther E, Ritter R, Apecechea M, et al.
Sustained improvements in patients with
dementia of Alzheimer’s type (DAT) 6 months
after termination of Cerebrolysin therapy. 
J Neural Transm. 2000; 107: 815–29.
255. Melnikova I. Therapies for Alzheimer’s
disease. Nat Rev Drug Discov. 2007; 6:
341–2.
256. Lleó A, Greenberg S, Growdon J. Current
pharmacotherapy for Alzheimer’s disease.
Annu Rev Med. 2006; 57: 513–33.
257. Bureeva S, Andia-Pravdivy J, Kaplun A.
Drug design using the example of the
complement system inhibitors’ develop-
ment. Drug Discov Today. 2005; 10:
1535–42.
258. Makrides S. Therapeutic inhibition of the
complement system. Pharmacol Rev.
1998; 50: 59–87.
© 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
